topical composition, and, use of topical composition

专利摘要:
topical gel, and, use of topical gel are provided, according to some embodiments of the invention topical gels that can release nitric oxide. methods of using such topical gels to treat wounds and other skin conditions are also provided. topical gels comprise polysiloxane macromolecules functionalized by diazeniotndiolate.
公开号:BR112012003792B1
申请号:R112012003792
申请日:2010-08-20
公开日:2020-05-19
发明作者:Stasko Nathan；R Joshi Pranav；Bauman Susanne
申请人:Novan Inc；
IPC主号:

专利说明:

TOPICAL COMPOSITION AND USE OF TOPICAL COMPOSITION CROSS-REFERENCE WITH RELATED ORDERS
[0001] This application claims the priority of U.S. Conditional Application Series No. 61 / 235,933, filed on August 21, 2009 whose disclosure is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to topical gels that can release nitric oxide controllably. The present invention also concerns methods of using topical gels that can release nitric oxide controllably.
BACKGROUND OF THE INVENTION
[0003] The skin has a myriad of functions including skin protection against pathogens and excessive water loss, isolation, temperature regulation, sensation and protection of vitamin B folates. As such, skin damage or disease can significantly affect health of a person or animal. In addition, such damage or illness can cause irritation, pain or other discomfort and can undesirably affect the physical appearance of the person or animal.
[0004] An important aspect for the treatment of many skin damages and diseases, including wounds and burns, is the control of the infection, which can facilitate the healing process. Topical medications are commonly used tools to protect wounds and other skin diseases from infection. Antimicrobial agents are often incorporated into topical medications and wound dressings to treat and prevent infection. However, there may be disadvantages associated with the use of antimicrobial agents. It has been observed that an increasing number of pathogens have developed resistance to conventional antibiotic treatments. According to statistics, antibiotic resistant pathogens are the primary reason for most all infections
Petition 870200037495, of 03/20/2020, p. 10/73
2/53 lethal nosocomials. See Robson et al., Surg. Clin. N. Am. 77, 637-650 (1977). In addition, many antimicrobial agents not only kill pathogens, but also pose a threat to the proliferation of granulation tissue, fibroblasts and keratinocytes that can help with the wound healing process. In addition, some antimicrobial agents can cause allergic reactions in some patients.
[0005] Nitric oxide is known to have a broad spectrum of antimicrobial activity and can be used as an alternative to conventional antibiotics for drug-resistant bacteria. In addition, some recent studies have shown that nitric oxide can also play an important role in the wound healing process by promoting angiogenesis by simulating vascular endothelial development factor (VEGF) and increasing fibroblast collagen synthesis. See, Schaffer MR, et al., Diabetes-impaired healing and reduced wound nitric oxide synthesis: A possible pathophysiologic correlation. Surgery 1997; 121 (5): 513-9; and Shi HP, et al., The role of iNOS in wound healing. Surgery 2001; 130 (2): 225-9. In this way, nitric oxide has a promising addition and / or alternative to conventional antibiotic treatments. In addition, nitric oxide has been shown to have other beneficial properties, including reduced inflammation and participation in biochemical wound healing cascades. unfortunately, the relationship between exogenously applied concentrations of nitric to promote healing, which mediate inflammation or treat infection is clearly understood.
[0006] Nitric oxide is a gas at room temperature and atmospheric pressure and has a short half-life in a physiological environment. Several small molecule nitric oxide donor prodrugs have been developed and have contributed greatly to the understanding of nitric oxide in various disease states. However, due to its stable results, indiscriminate NO release,
Petition 870200037495, of 03/20/2020, p. 11/73
3/53 monotypic nitric oxide release and inability of specific target tissue types, optimal solutions for the administration of nitric oxide out of its gaseous form have not yet been achieved. The reproducible release of the correct levels of nitric oxide for a given therapeutic indication is critical because the release of large amounts of nitric oxide can be toxic or create undesirable side effects such as an increase in inflammation. Therefore, it was challenging to use nitric oxide for topical therapeutic applications, particularly for the release of nitric oxide in a controlled manner from vehicles capable of targeting tissue structures. [0007] As an example, previous investigators explored the use of topical formulations containing a source of alkaline nitrite in combination with ascorbic acid or another organic acid which, in the mixture creates a fast nitric oxide release cake. While the antimicrobial efficacy of nitric oxide released through this method has been shown, this can result in decreased angiogenesis, increased inflammation and desired toxicity. Thus, there is a need for topical treatments and medications that can release nitric oxide by a controlled release method.
SUMMARY OF THE INVENTION
[0008] Topical gels that release nitric oxide (NO) are supplied according to the embodiments of the invention. In some embodiments of the invention, topical gels include diazeniodiolate functionalized polysiloxane macromolecules and a hydrophobic non-aqueous gel base. In some embodiments, the hydrophobic non-aqueous gel base is a silicone gel. In addition, in some embodiments, polysiloxane macromolecules functionalized by diazeniodiolate and gel excipients have an octanol / water division coefficient in the range of 0.1 to 7.
[0009] In some embodiments of the invention, topical gels
Petition 870200037495, of 03/20/2020, p. 12/73
4/53 include polysiloxane macromolecules functionalized by diazeniodiolate and a hydrophilic gel base. As such, in some embodiments, polysiloxane macromolecules functionalized by diazeniodiolate and gel excipients have an octanol / water coefficient in the range of -2 to 0. [0010] In some embodiments of the invention, the concentration of polysiloxane macromolecules functionalized by diazeniodiolate in the gel is in a range of 0.1 to 20% by weight.
[0011] In some embodiments of the invention, polysiloxane macromolecules functionalized by diazeniodiolate have a hydrodynamic radius in the range of 1000 nm to 10 microns. In some embodiments of the invention, polysiloxane macromolecules functionalized by diazeniodiolate have a hydrodynamic radius in a range from 1 nm to 100 nm.
[0012] The storage of nitric oxide from the gels can be cut. In some embodiments, the storage of nitric oxide per gram is in the range of 0.1 pmol NO / g to 100 nmol / g gel. In some embodiments, the storage of nitric oxide per gram is in the range of 1 nmol NO / g to 10 pmol / g of gel. In some embodiments, the storage of nitric oxide per gram is in the range of 10 pmol NO / g to 1 mmol / g of gel.
[0013] In some embodiments of the invention, gels further include other therapeutic agents, such as an anti-acne agent, antimicrobial agent, benzoyl peroxide or a corticosteroid.
[0014] Also provided here are methods of treating wounds that include wounds that comprise the application of the topical gel according to an embodiment of the invention. In the particular embodiments, the methods include treating burns and treating acne. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] The attached drawings, which are included to provide a
Petition 870200037495, of 03/20/2020, p. 13/73
5/53 further understanding of the invention and are incorporated and constitute a part of this application, illustrate certain embodiments of the invention.
[0016] Figure 1 is a schematic for the synthesis of polysiloxane macromolecules functionalized by diazeniodiolate according to some embodiments of the invention.
[0017] Figure 2A is a graph illustrating the effectiveness of polysiloxane macromolecules functionalized by diazeniodiolate according to some embodiments of the invention in the death of P. aeruginosa.
[0018] Figure 2B is a graph illustrating the efficacy of diazeniodiolate functionalized polysiloxane macromolecules according to some embodiments of the invention in the death of MRSA.
[0019] Figure 3 is a graph illustrating the dose dependence of the efficacy of polysiloxane macromolecules functionalized by diazeniodiolate according to some embodiments of the invention in the death of P. aeruginosa.
[0020] Figure 4 is a graph illustrating the dose dependence of diazeniodiolate functionalized polysiloxane macromolecules according to some embodiments of the invention in wound healing.
[0021] Figure 5 shows a series of images of wound healing versus time for the graph in Figure 4.
[0022] Figure 6 provides the release of NO versus time for a gel according to an embodiment of the invention.
[0023] Figure 7 shows the NO release curves that show a change in the genetic profile as a function of excipients versus polysiloxane macromolecules functionalized by diazeniodiolate only.
[0024] Figure 8 shows that the stability of NO in gel over time decreases as a function of gel components.
[0025] Figure 9 shows the antimicrobial time-death of P.
Petition 870200037495, of 03/20/2020, p. 14/73
6/53 aeruginosa for polysiloxane macromolecules functionalized by diazeniodiolate vs. hydrophobic gel formulated in equivalent concentrations of silica.
[0026] Figure 10 shows the effectiveness of hydrophilic gel versus time death. Hydrophobic against P. aeruginosa for particular gels according to some embodiments of the invention.
[0027] Figure 11 shows the dose and time-effectiveness of polysiloxane macromolecules functionalized by diazeniodiolate according to an embodiment of the invention against P. acnes.
[0028] Figure 12 shows the dose and time-effectiveness of polysiloxane macromolecules functionalized by diazeniodiolate according to an embodiment of the invention against T. rubrum.
DETAILED DESCRIPTION OF WAYS OF CARRYING OUT THE INVENTION
[0029] The foregoing and other aspects of the present invention will now be described in more detail with respect to the description and methodologies provided herein. It must be estimated that the invention can be embodied in different forms and should not be construed as limited to the embodiments presented here. Instead, these embodiments are provided so that this disclosure will be complete and complete and will fully address the scope of the invention for those skilled in the art.
[0030] The terminology used in describing the invention here is for the purpose of describing the particular embodiments only and is not intended to be limiting of the invention. As used in describing the embodiments of the invention and the appended claims, the singular forms "one", "one", "o" and "a" are also intended to include plural forms, unless the context clearly dictates other way. Also, as used here, "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items. In addition, the term
Petition 870200037495, of 03/20/2020, p. 15/73
7/53 “about”, as used here when referring to a measurable value such as an amount of a compound, dose, time, temperature and others, is understood to cover variations of 20%, 10%, 5%, 1 %, 0.5% or 0.1% of the specified quantity. It will also be understood that the terms "understands" and / or "understands", when used in this specification, specifies the presence of established characteristics, integers, steps, operations, elements and / or components, but does not prevent the presence or addition of one or more other characteristics, integers, steps, operations, elements, components, and / or groups of these. Unless otherwise defined, all terms, including technical and scientific terms used in the description, have the same meaning as commonly understood by a person of ordinary skill in the technique to which this invention belongs.
[0031] All patents, patent applications and publications referred to herein are incorporated by reference in their entirety. In the event of conflicting terminology, this specification is controlling.
[0032] The embodiments described in one aspect of the present invention are not limited to the described aspects. The embodiments can also be applied to a different aspect of the invention as long as the embodiments do not avoid these aspects of the operating invention for their intended purpose.
Chemical Definitions
[0033] As used here, the term "alkyl" refers to C1-20 inclusive, linear (i.e., "straight chain"), branched or cyclic saturated or at least partially and, in some cases, fully hydrocarbon chains unsaturated (i.e., alkenyl and alkynyl), including, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, octyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, octenyl groups, butadienyl, propynyl, butynyl, pentynyl, hexynyl, heptinyl and alenyl. “Branched”
Petition 870200037495, of 03/20/2020, p. 16/73
8/53 refers to an alkyl group, in which a lower alkyl group, such as methyl, ethyl or propyl, is attached to a linear alkyl chain. Exemplary branched alkyl groups include, but are not limited to, isopropyl, isobutyl, tert-butyl. "Lower alkyl" refers to an alkyl group having 1 to about 8 carbon atoms (i.e., a C1-8 alkyl), for example, 1, 2, 3, 4, 5, 6, 7 or 8 atoms of carbon. "Upper alkyl" refers to an alkyl group having about 10 to about 20 carbon atoms, for example, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms . In certain embodiments, "alkyl" refers, in particular, to straight chain C15 alkyls. In other embodiments, "alkyl" refers, in particular, to C1-5 branched chain alkyls.
[0034] Alkyl groups can be optionally substituted (a "substituted alkyl") with one or more alkyl group substituents, which can be the same or different. The term "alkyl group substituent" includes, but is not limited to, alkyl, substituted alkyl, halo, arylamino, acyl, hydroxyl, aryloxy, alkoxyl, alkylthio, arylthio, aralkyloxyl, aralkylthio, carboxyl, alkoxycarbonyl, oxo and cycloalkyl. One or more substituted or unsubstituted oxygen, sulfur or nitrogen atoms can be optionally inserted together with the alkyl chain, where the nitrogen substituent is hydrogen, lower alkyl (also referred to here as "alkylaminoalkyl") or aryl.
[0035] Thus, as used herein, the term "substituted alkyl" includes alkyl groups, as defined herein, in which one or more atoms or functional groups of the alkyl group are replaced by another atom or functional group, including for example, alkyl, substituted alkyl, halogen, aryl, substituted aryl, alkoxy, hydroxyl, nitro, amino, alkylamino, dialkylamino, sulfate and mercapto.
[0036] The term "aryl" is used here to refer to an aromatic substituent which can be an aromatic ring or multiple aromatic rings that
Petition 870200037495, of 03/20/2020, p. 17/73
9/53 are fused together, covalently bonded or bonded to a common group, such as, but not limited to, a portion of methylene or ethylene. The common bonding group can also be a carbonyl, as in benzophenone or oxygen, as in diphenyl ether or nitrogen, as in diphenylamine. The term "aryl" specifically covers aromatic heterocyclic compounds. Aromatic rings can comprise phenyl, naphthyl, biphenyl, diphenyl ether, diphenylamine and benzophenone, among others. In particular embodiments, the term "aryl" means a cyclic aromatic comprising about 5 to about 10 carbon atoms, for example, 5, 6, 7, 8, 9 or 10 carbon atoms and including aromatic rings of 5- and 6-membered hydrocarbon and heterocyclic.
[0037] The aryl group can be optionally substituted (a "substituted aryl") with one or more aryl group substituents, which can be the same or different, where the "aryl group substituent" includes alkyl, substituted alkyl, aryl , substituted aryl, aralkyl, hydroxyl, alkoxyl, ariloxila, aralquiloxila, carboxyl, acyl, halo, nitro, alkoxycarbonyl, ariloxicarbonila, aralcoxicarbonila, aciloxila, acylamino, aroylamino, carbamoyl, alquilcarbamoila, dialquilcarbamoila, arylthio, alkylthio, alkylene , and ^-NR'R ”, Where R ¹ and R” can independently be hydrogen, alkyl, substituted alkyl, aryl, substituted aryl and aralkyl.
[0038] Thus, as used herein, the term "substituted aryl" includes aryl groups, as defined here, in which one or more atoms or functional groups of the aryl group are replaced by another atom or functional group, including, for example , alkyl, substituted alkyl, halogen, aryl, substituted aryl, alkoxy, hydroxyl, nitro, amino, alkylamino, dialkylamino, sulfate and mercapto. Specific examples of aryl groups include, but are not limited to, cyclopentadienyl, phenyl, furan, thiophene, pyrrole, pyran, pyridine, imidazole, benzimidazole, isothiazole, isoxazole, pyrazole, pyrazine, triazine, pyrimidine, quinoline, isoquinoline, indole, carbazole and others.
Petition 870200037495, of 03/20/2020, p. 18/73
10/53
[0039] "Cyclic" and "cycloalkyl" refers to a non-aromatic mono or multicyclic ring system of about 3 to about 10 carbon atoms, for example 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. The cycloalkyl group can optionally be partially unsaturated. The cycloalkyl group can also be optionally substituted by an alkyl group substituent as defined herein, oxo, and / or alkylene. These can optionally be inserted along the cyclic alkyl chain one or more substituted or unsubstituted oxygen, sulfur or nitrogen atoms, where the nitrogen substituent is hydrogen, alkyl, substituted alkyl, aryl or substituted aryl, thereby providing a heterocyclic group. Representative monocyclic cycloalkyl rings include cyclopentyl, cyclohexyl and cycloheptyl. Multicyclic cycloalkyl rings include adamantila, octahydronaftila, decalin, camphor, camphan and noradamantila.
[0040] "Alkoxyl" refers to an alkyl-O- group in which alkyl is as previously described. The term "alkoxy" as used herein, can refer to, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, f-butoxy and pentoxyl. The term "oxyalkyl" can be used interchangeably with "alkoxy". In some embodiments, the alkoxy has 1, 2, 3, 4 or 5 carbons.
[0041] "Aralkyl" refers to an arylalkyl group in which aryl and alkyl are previously described and included substituted aryl and substituted alkyl. Exemplary aralkyl groups include benzyl, phenylethyl and naphthylmethyl.
[0042] "Alkylene" refers to a straight or branched bivalent aliphatic hydrocarbon group having from 1 to about 20 carbon atoms, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 , 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms. The alkylene group can be straight, branched or cyclic. The alkylene group can also be optionally unsaturated and / or substituted by one or more "alkyl group substituents." These can be
Petition 870200037495, of 03/20/2020, p. 19/73
11/53 optionally inserted along the alkylene group one or more substituted or unsubstituted oxygen, sulfur or nitrogen atoms (also referred to herein as "alkylaminoalkyl"), where the nitrogen substituent is alkyl as previously described. Exemplary alkylene groups include methylene (-CH2-); ethylene (-CH2-CH2-); propylene (- (CH2) 3-); cyclohexylene (C6H10-); -CH = CH-CH = CH-; -CH = CH-CH2-; where each q and q is independently an integer from 0 to about 20, for example 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 , 15, 16, 17, 18, 19 or 20 and R is hydrogen or lower alkyl; methylenedioxy (-O-CH2-O-); and ethylenedioxy (-O- (CH2) 2-O-). An alkylene group can have about 2 to about 3 carbon atoms and can still have 6 to 20 carbons.
[0043] "Arylene" refers to a divalent aryl group. An exemplary arylene is phenylene, which may have ring carbon atoms available for bonding in ortho, meta positions or with respect to each other, that is, respectively. The arylene group can also be naptilene. The arylene group can be optionally substituted (a "substituted arylene") with one or more "aryl group substituents" as defined here, which can be the same or different.
[0044] "Aralkylene" refers to a divalent group that contains both alkyl and aryl groups. For example, aralkylene groups can have two alkyl groups and an aryl group (i.e., -alkyl-aryl-alkyl-), an alkyl group and an aryl group (i.e., -alkyl-aryl-) or two aryl groups and an alkyl group (i.e., -aryl-alkyl-aryl-).
[0045] The term "amino" and "amine" refer to nitrogen-containing groups, such as NR3, NH3, NHR2 and NH2R, where R can be alkyl, branched alkyl, cycloalkyl, aryl, alkylene, arylene, aralkylene. In this way, "amino" as used here, can refer to a primary amine, a secondary amine or a tertiary amine. In some embodiments, an R of an amino group can be a stabilized cation
Petition 870200037495, of 03/20/2020, p. 20/73
12/53 diazeniodiolate (i.e., NONO-X +).
[0046] The terms "cationic amine" and "quaternary amine" refer to an amino group having an additional group (that is, a quarter), for example, a hydrogen or an nitrogen-bonded alkyl group. In this way, cationic and quaternary amines carry a positive charge.
[0047] The term "alkylamine" refers to the group -alkyl-NH2.
[0048] The term "carbonyl" refers to the group - (C = O) -.
[0049] The term "carboxyl" refers to the group -COOH- and the term "carboxylate" refers to an anion formed from a carboxyl group, that is, -COO ^- .
[0050] The terms "halo", "halide" or "halogen" as used here, refer to groups of fluorine, chlorine, bromine and iodine.
[0051] The term "hydroxyl" and "hydroxy" refer to the -OH group.
[0052] The term "hydroxyalkyl" refers to an alkyl group substituted by an -OH group.
[0053] The term "mercapto" or "uncle" refers to the group -SH. The term "silyl" refers to groups that comprise silicon (Si) atoms.
[0054] As used herein, the term "alkoxysilane" refers to a compound comprising one, two, three or four alkoxy groups attached to a silicon atom. For example, tetraalkoxysilane refers to Si (OR) 4, where R is alkyl. Each alkyl group can be the same or different. An "alkylsilane" refers to an alkoxysilane in which one or more of the alkoxy groups has been replaced by an alkyl group. In this way, an alkylsilane comprises at least one alkyl-Si bond. The term "fluorinated silane" refers to an alkylsilane in which one of the alkyl groups is replaced by one or more fluorine atoms. The term “cationic or anionic silane” refers to an alkylsilane in which one of the alkyl groups is still replaced by an alkyl substituent that has a positive (ie, cationic) or negative (ie, anionic) or can be tornado loaded
Petition 870200037495, of 03/20/2020, p. 21/73
13/53 (that is, it is ionizable) in a particular environment (that is, in vivo).
[0055] The term "silanol" refers to the Si-OH group.
[0056] They are provided, according to some topical medicaments embodiments that include macromolecules that release NO. In some embodiments, the macromolecules that release NO non-macromolecules of polysiloxane functionalized by diazeniodiolate. In addition, in some embodiments, medications include polysiloxane macromolecules functionalized by diazeniodiolate in a gel.
[0057] In some embodiments of the invention, the properties of the gel are selected based on the properties of the polysiloxane macromolecules functionalized by diazeniodiolate and the indication for which the topical gel should be used, such that the interaction of the properties of the gel, macromolecule and skin environment act to provide the desired NO release profile. At the same time, the gel must be adequately stable and resist decomposition before topical application.
[0058] Polysiloxane Macromolecules Functionalized by Diazeniodiolate
[0059] The term "polysiloxane macromolecules functionalized by diazeniodiolate" refers to co-condensed polysiloxane macromolecules functionalized with diazeniumdiolate, such as the NO-releasing particles described in US Publication No. 2009/0214618, the disclosure of which is incorporated by reference here in its entirety. Such particles can be prepared by the methods described herein.
[0060] In some embodiments of the invention, the nitric oxide donor can be formed from an aminoalkoxysilane by a pre-loading method and the co-condensed silane network can be synthesized from the condensation of a mixture of silane that includes an alkoxysilane and aminoalkoxysilane to form a co-condensed siloxane network
Petition 870200037495, of 03/20/2020, p. 22/73
14/53 modified by nitric oxide donor. As used here, the "preloading method" means that the aminoalkoxysilane is "pre-treated" or "preloaded" with nitric oxide prior to co-condensation with alkoxysilane. In some embodiments, nitric oxide preloading can be performed by chemical methods. In another embodiment, the “preload” method can be used to create co-condensed siloxane networks and more densely functionalized materials with NO donors.
[0061] The co-condensed siloxane network can be and uniform silica particles, a collection of silica particles with a variety of sizes, amorphous silica, fumigated silica, nanocrystalline silica, ceramic silica, colloidal silica, a coating of silica, a silica film, organically modified silica, mesoporous silica, silica gel, bioactive glass or any suitable form or state of silica.
[0062] In some embodiments, alkoxysilane is a tetraalkoxysilane having the formula Si (OR) 4, where R is an alkyl group. The R groups can be the same or different. In some embodiments, tetraalkoxysilane is selected as tetramethyl orthosilicate (TMOS) or tetraethyl orthosilicate (TEOS). In some embodiments, the aminoalkoxysilane has the formula: R ”- (NH-R ') nSi (OR) 3, where R is alkyl, R' is branched alkylene, alkylene or aralkylene, n is 1 or 2 and R ”Is selected from the group consisting of alkyl, cycloalkyl, aryl and alkylamine.
[0063] In some embodiments, the aminoalkoxysilane can be selected from N- (6-aminoexyl) aminopropyltrimethoxysilane (AHAP3); N- (2aminoethyl) -3-aminopropyltrimethoxysilane (AEAP3); (3-trimethoxysilylpropyl) diethylenetriamine (DET3); (amino ethylaminomethyl) phenethyltrimethoxysilane (AEMP3); [3- (methylamino) propyl] trimethoxysilane (MAP3); N-butylaminopropyltrimethoxysilane (n-BAP3); t-butylamino-propyltrimethoxysilane (t
Petition 870200037495, of 03/20/2020, p. 23/73
15/53
BAP3); N-ethylaminoisobutyltrimethoxysilane (EAiB3); N-phenylaminopropyltrimethoxysilane (PAP 3); and N-cyclohexylaminopropyltrimethoxysilane (cHAP3).
[0064] In some embodiments, the aminoalkoxysilane has the formula: NH [R'-Si (OR) 3] 2, where R is alkyl and R 'is alkylene. In some embodiments, the aminoalkoxysilane can be selected from bis (3triethoxysilylpropyl) amine, bis- [3- (trimethoxysilyl) propyl] amine and bis - [(3trimethoxysilyl) propyl] ethylenediamine.
[0065] In some embodiments, as previously described, the aminoalkoxysilane is preloaded for the release of NO and the amino group is replaced by a diazeniodiolate. Therefore, in some embodiments, the aminoalkoxysilane has the formula: R ”-N (NONO ^- X +) - R'Si (OR) 3, where R is alkyl, R 'is alkylene or aralkylene, R” is alkyl or alkylamine and X ⁺ is a cation selected from the group consisting of Na ⁺ , K ⁺ , Cs ⁺ , Li ⁺ , NH4 or another quaternary ammonium cation.
[0066] In some embodiments of the invention, the functional amino alkoxysilane of diazeniodiolate can be protected by O ² prior to the preparation of macromolecules that release nitric oxide. Such O ² protected diazeniodiolate aminoalkoxysilanes may have the formula: R ”-N (NONO-R” ') - R'-Si (OR) 3, where each R is independently H, alkyl or substituted alkyl, R' is substituted or unsubstituted alkylene, substituted or unsubstituted arylene, substituted or unsubstituted alkylarylene or substituted or unsubstituted arylalkylene, R ”is H, alkyl or substituted alkyl and R” 'is a protecting group that communicates enzymatic trigger mechanisms, photolytic or detiolation. Such protecting groups are known to those skilled in the art of forming diazeniodiolates protected by O ² .
[0067] The chemical composition of the siloxane network, (for example, quantity or chemical composition of the aminoalkoxysilane), the porosity of the
Petition 870200037495, of 03/20/2020, p. 24/73
16/53 silica network within the macromolecular structure, the size of the co-condensed silica particles and the nitric oxide loading conditions (for example, the solvent and the base) can be varied to optimize the amount and duration of release of nitric oxide. In this way, in some embodiments, the composition of the silica particles can be modified to regulate the average NO release life from the silica particles with average nitric oxide release lives ranging from slow, defined by t1 values. / 2 greater than 60 minutes fast, defined by / 1/2 values ranging from 30 seconds to 10 minutes.
[0068] In some embodiments of the invention, the co-condensed solixane network of nitric oxide-releasing silica particles is formed of at least one additional silane which modifies the surface charge and / or hydrophilicity / hydrophobicity of the silica product co-condensate that affects the octanol / water division coefficient of the macromolar release vehicle. These parameters control the path of penetration into the skin, depth of penetration and diffusion of polysiloxane macromolecules modified by diazeniodiolate outside topical gel vehicles. Any suitable alkoxysilane that communicates surface charge to the diazeniodiolate modified polysiloxane macromolecule can be used. Thus, in some embodiments, the additional alkoxysilane includes a cationic alkoxysilane, such as (2-N-benzylaminoethyl) -3-aminopropyltrimethoxysilane, hydrochloride; bis (methoxyethyl) -3-trimethoxysilylpropylammonium chloride; N-N-didecyl-N-methyl-N- (3-trimethoxysilyl) ammonium chloride; N-trimethioxysilylpropyl-N, N, N-trimethyl ammonium chloride; octadecylbis chloride (triethoxysilylpropyl) -ammonium and octadecyldimethyl chloride (3-trimethoxysilylpropyl) ammonium In some embodiments, the additional alkoxysilane may include an anionic alkoxysilane, such as 3-trihydroxysilylpropylmethyl phosphonate, sodium salt and carboxyethylsilanotriol, sodium salt.
[0069] Any suitable alkoxysilane that can communicate
Petition 870200037495, of 03/20/2020, p. 25/73
17/53 hydrophilic properties to the polysiloxane macromolecule modified by diazeniodiolate, can be used. Alkoxysilanes containing repeating poly (ethylene) oxide groups can be used to increase the wetting of NO release particles which help to improve biocompatibility in topical application and also enhance the water absorption rate in the co-condensed siloxane coating. Surface hydrophilicity can thus be used to enhance the NO release kinetics of diazeniodiolated aminoalkoxysilane derivatives. Therefore, in some embodiments, the multifunctional alkoxysilane may include a hydrophilic silane, such as N-triethoxysilylpropyl) -O-polyethylene oxide; N3- [amino (polypropyleneoxy)] aminopropyltrimethoxy silane; ethyl bis- [3 (triethoxysilylpropoxy) -2-hydroxypropoxy] polyoxide; ethylene bis (3-triethoxysilylpropyl) polyoxide (25-30);
[hydroxy (polyethyleneoxy) propyl] -triethoxysilane and 2 [methoxy (polyethyleneoxy) propyl] -trimethoxysilane.
[0070] Any suitable alkoxysilane that can communicate hydrophobic properties to the diazeniodiolate modified polysiloxane macromolecule can be used. Hydrophobic silanes are known to those skilled in the art to increase the lipophilicity of particle surfaces. In some embodiments, the additional alkoxysilane may include linear alkyl, branched and cyclic alkylalkoxysilanes having at least three carbon atoms, substituted and unsubstituted phenyl alkoxysilanes and fluorinated alkoxysilanes. Exemplary fluoroalkoxysilanes may include heptadecafluoro-1,1,2-2-tetrahydrodecyl) triethoxysilane (shown in Figure 2I), (3,3,3-trifluoropropyl) trimethoxysilane, (perfluoroalkyl) ethyltriethoxysilane, nonafluoroexiltrimethoxysilane, nonafluoroexiltrimethoxylane, 1,2,2tetrahydroxy) triethoxysilane and (tridecafluoro-1,1,2,2) Petition 870200037495, of 3/20/2020, p. 26/73
18/53 tetrahydroxy) trimethoxysilane.
[0071] The hydrophilicity of polysiloxane macromolecules functionalized by diazeniodiolate can be estimated by the use of a water / octanol division coefficient. See Octanol-Water Partition Coefficients: Fundamentals and Physical Chemistry, Vol. 2 of Wiley Series in Solution Chemistry. Chichester: John Wiley & Sons Ltd .. (1997), which is incorporated herein by reference in its entirety. For example, hydrophobic diazeniodiolate functionalized polysiloxane macromolecules may have a water / octanol division coefficient in the range of 0.1 to 7 and hydrophilic diazeniodiolate functionalized polysiloxane macromolecules may have a water / octanol division coefficient in one range from -2 to 0.
[0072] In some embodiments of the invention, the hydrodynamic radius of the macromolecule it releases is within a range of 1 nm to 100 nm, which can maximize penetration of trans-epidermal skin and intensify the release of nitric oxide to deeper structures of the skin or the size of the macromolecular structure can be selected to be in a range of 101 nm to 1000 nm to selectively accommodate polysiloxane macromolecules modified by diazeniodiolate in the horny extract and limit skin penetration, systemic absorption and any toxicity resulting from the macromolecular structure or the size of the macromolecule structure can be selected to be in a range from 1000 nm to 10,000 nm for penetration into the target skin through the trans-follicular pathway. Selective release to the horny extract, epidermis or dermis can be achieved by varying the particle size. The skin naturally has a low permeability to particulate materials and the horny extract provides an effective barrier to most of the more inorganic nano-sized particles with gold nanoparticles, silver nanoparticles, quantum dots, titanium dioxide and zinc oxide being the most extensively
Petition 870200037495, of 03/20/2020, p. 27/73
19/53 studied. See, for example, Baroli, B., Penetration of Nanoparticles and Nanomaterials in the Skin: Fiction or Reality Journal of Pharmaceutical Sciences, 2009 December; 99: 21-50. Despite the current understanding of a person skilled in the art regarding skin penetration, the penetration of silica particles into the skin as a function of size is poorly understood.
[0073] Polysiloxane macromolecules functionalized by diazeniodiolate can be present in medications according to the embodiments of the invention in any suitable concentration, but in some embodiments, polysiloxane macromolecules functionalized by diazeniodiolate are present in medications in a concentration sufficient to increase the wound healing rate, decrease inflammation and / or graft an antimicrobial effect. In the particular embodiments, the concentration of polysiloxane macromolecules functionalized by diazeniodiolate is in the range of 0.01 percent to 20 percent w / w. In some embodiments, the concentration of polysiloxane macromolecules functionalized by diazeniodiolate in the drug can be adjusted to modulate the amplitude of nitric oxide release (mol NO / g of drug) by changing the weight percentage in the gel or varying the charge of nitric oxide in the macromolecular structure to create a desirable therapeutic result.
[0074] In some embodiments, to avoid platelet activation and aggregation, the final NO storage per gram of gel can be in the range of 0.1 pmol NO / g of gel to 100 nmol / g of gel. In some embodiments, to reduce inflammation and associated inflammatory response factors, the final NO storage per gram of gel can be in the range of 100 pmol NO / g gel to 1 pmol NO / g gel. In some embodiments, to promote wound healing, the
Petition 870200037495, of 03/20/2020, p. 28/73
20/53 storage of final NO per gram of gel can be in a range of 1 nmol NO / g of gel to 10 μmol of NO / g of gel. In some embodiments, to exert antimicrobial activity, the final NO storage per gram of gel can be in the range of 10 μmol NO / g of gel to 1 mmol NO / g of gel. In some embodiments, to treat biopellets by dispersion, the final NO storage per gram of gel can be in a range of 10 nmol NO / g of gel to 1 μmol NO / g of gel, and in some embodiments, to treat biopellets by direct microbiocidal activity, the final NO storage per gram of gel can be in the range of 100 μmol NO / g of gel to 1 mmol NO / g of gel.
Topical gels
[0075] The properties of topical gels, including the NO release profile, can be cut by selecting the gel composition. Gels can also provide beneficial or therapeutic action to the injured skin or layer (for example, moisten, absorb wound exudate, provide an occlusive barrier, etc.) that can directly affect skin conditions or heal the wound. The excipients that form the gels can also indirectly affect wound healing by affecting the stability of polysilane macromolecules functionalized by diazeniodiolate or other therapeutic agents within the drug and / or controlling the decomposition rates of NO donors for the generation of nitric oxide. The intrinsic pH of the topical gel can be raised to between 8 and 10 to maintain the stability of the NO donor and react with the acid mantle on the skin surface to neutralize the pH and initiate the decomposition of the nitric diazeniodiolate oxide donors.
[0076] The excipients for use in topical gels are well known in the art and examples can be found in the Handbook of Pharmaceutical Excipients (Rowe, RC et al, APhA Publications,. 5 ^th ed . , 2005). Exemplary excipients can include waxes, various sugars and types of starch, polymers, gels, emollients, thickening agents,
Petition 870200037495, of 03/20/2020, p. 29/73
21/53 rheology, humectants, glycerol, basic organic compounds, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and solvents. Examples of rheology modifiers include Carbopol, hydroxypropyl cellulose, C26-28 alkyl dimethicone, C26-28 alkyl methicone, polyphenylisquioxane, trimethylsiloxysilicate, cross-polymers of cyclopentasiloxane and dimethicone / vinyltrimethylsiloxysilicate, fumigated silica (e.g. of these. Examples of emollients include glycerin, pentylene glycol, sodium pyrrolidone carboxylic acid, lanolin, saccharide isomerate, stearoxy dimethicone, stearyl dimethicone, and mixtures thereof. Emollients can be useful to prevent dehydration of the horny extract that occurs due to the use of anhydrous solvents in the formulation. Examples of organic bases include 2-amino-2-methyl propanol, niacinamide, methanolamines, triethanolamines, Trisamino, AMP-95, AmP-Ultra PC 2000, triisopropanolamine, diisopropanolamine, Neutrol TE, Ethomeen, and mixtures thereof. The organic base can make the pH of the medication basic or neutral and can directly affect the release of NO from the diazeniodiolate groups by decreasing donor decomposition with increasing alkalinity. [0076] Other exemplary excipients include water-soluble progeny. A water-soluble progeny is an additive that can facilitate water absorption and diffusion in the gel. Any suitable progeny can be used, but in some embodiments, the progeny can include sodium chloride, potassium chloride, sucrose, glucose, lactose, sorbitol, xylitol, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol or mixtures thereof. Electrolytes, such as KC1, can also be added as excipients to enhance the stability of diazeniodiolate NO donors.
[0077] Polymers can also act as excipients in topical gels. Exemplary polymers include hydrophilic polyurethanes, hydrophilic polyacrylates, co-polymers of carboxymethylcellulose and acrylic acid, N-vinylpyrrolidone, poly (hydroxy acids), polyanhydrides,
Petition 870200037495, of 03/20/2020, p. 30/73
22/53 polyiortoesters, polyamides, polycarbonates, polyalkylenes (for example, polyethylene and polypropylene), polyalkylene glycols (for example, poly (ethylene glycol)), alkylene polyoxides (for example, ethylene polyoxide), polyalkylene terephthalates (for example, polyethylene terephthalate), polyvinyl alcohol, polyvinyl ethers, polyvinyl esters, polyvinyl halides (e.g. poly (vinyl chloride)), polyvinylpyrrolidone, polysiloxanes, polyvinyl acetates), polystyrenes, polyurethane, cellulose derivatives, cellulose, polyurethane, cellulose, polyurethane, cellulose, cellulose, cellulose, polyurethane, cellulose, cellulose, cellulose, cellulose, cellulose, cellulose, cellulose, polyurethane, cellulose, cellulose, cellulose, cellulose. (acrylic acid), poly (acrylic acid) derivatives, acrylic acid copolymers, methacrylic acid, methacrylic acid derivatives, methacrylic acid copolymers, poly (butyric acid), poly (valeric acid), poly (lactide-co-caprolactone ), copolymers thereof and combinations thereof.
[0078] In some embodiments of the invention, polymers can be superabsorbent polymers (SAPs). A polymer is considered super-absorbent, as defined by IUPAC, as a polymer that can absorb and retain extremely large amounts of water in relation to its own mass. SAPs can absorb water up to 500 times my own weight and can expand to 1000 times its original volume. Particular SAPs of interest include sodium polyacrylate, Tecophilic TG-2000 polyurethane and polymers prepared by the use of polyacrylamide copolymer, anhydrous melamine ethylene copolymer, crosslinked carboxymethylcellulose, polyvinyl alcohol copolymers, polyvinylpyrrolidone and polyvinylpyrrolidone and polyoxylpyrrolidone. . In some embodiments, SAP can absorb water from the wounded bed, thereby causing NO to be released from the polysilane macromolecules functionalized by diazeniodiolate.
[0079] In some embodiments of the invention, polymers that are relatively hydrophobic can be used. Any suitable hydrophobic polymer can be used. However, exemplary polymers that are relatively hydrophobic include aromatic polyurethanes, rubber
Petition 870200037495, of 03/20/2020, p. 31/73
23/53 silicone, polysiloxanes, polycaprolactone, polycarbonate, polyvinyl chloride, polyethylene, poly-L-lactide, poly-DL-glycolide, polyetheretherketone (PEEK), polyamide, polyimide and polyvinyl acetate. In addition, a hydrophobic gel base and / or rheology modifier can be used.
[0080] In some embodiments of the invention, polymers can act as thickening agents in medicines. Specifically, the polymeric portion of the gel can act as a viscoelastic substance and can retain the gel at the application site, along with the polysilane-functionalized diazeniodiolate macromolecules dispersed therein.
[0081] In some other embodiments, a gel that includes a polymer may have such dispersibility that it forms a thin film when applied to the skin surface. This film can enable the application of the contained polysiloxane macromolecules that release NO over a wide area and can serve as the polysiloxane macromolecules that release NO in the affected area of the skin.
[0082] Other excipients may include various ionic or non-ionic compounds to maintain the stability of the formulation, thus protecting from the removal of emulsion, sediment, agglomeration or degradation of the formulation's constituents that may reduce its therapeutic or aesthetic value.
[0083] Examples of conical compounds can include salts such as sodium chloride, potassium chloride; cationic, anionic or zwitterionic surfactants such as sodium dodecyl sulfate (SDS), perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), lauryl ammonium lauryl sulfate (ALS), sodium lauryl ether sulfate (SLES), benzyl sulfonate cetyl trimethylammonium (CTAB), cetylpyridinium chloride (CPC), ethoxylated tallow amine (POEA), benzalkonium chloride (BAC), benzethonium chloride, dodecyl betaine, cocamidopropyl betaine and cocoanfoglycinate.
[0084] Examples of non-ionic compounds that can act as
Petition 870200037495, of 03/20/2020, p. 32/73
24/53 excipients include non-ionic surfactants such as Pluronic, Tween, AMP and the Brij family of surfactants; and surfactants derived from biological sources, for example, synthetic or semi-synthetic surfactants, such as oleic acid, sorbitan trioleate, sorbitan monooleate, lecithin, cocamide MEA, cocamide DEA and cocamidopropyl betaine. Surfactants (both ionic and non-ionic) can reduce the interfacial surface energy and can facilitate the dispersion of the ointment or liquid over a wider area.
[0085] In some embodiments of the invention, solvent excipients can be used as a carrier vehicle for macromolecules that release NO and other excipients. The polymer chains can interact with the solvent and undergo expansion to form a network that can give the drug its elastic properties. In some embodiments of the drug, the solvent may evaporate on application, leading to a residual film of the polymer along with the trapped macromolecules that release NO.
Exemplary solvent excipients that may be useful in hydrophilic formulations may include dimethyl isosorbide, propylene glycol, glycerol, isopropanol, ethanol, benzyl alcohol, ethylene glycol, polyethylene glycol, ethoxy glycol or mixtures thereof. Exemplary solvent excipients that may be useful in hydrophobic formulations may include capric / caprylic triglycerides, isopropyl myristate, mineral oil, isododecane, isodecyl neopentanoate, butylene glycol, pentylene glycol, hexylene glycol, methoxy polyethylene glycol, cyclopentasiloxane, cyclopentyloxoxane, cyclopentyloxoxane, cyclopentasiloxane, cyclopentasiloxane, cyclopentyloxoxane, cyclopentasiloxane, cyclopentasiloxane, cyclopentasiloxane, cyclopentyloxoxane, cyclopentyloxane, cyclotentiloxane, cyclotentiloxane, cyclotentiloxane, cyclotentiloxane, cyclotentiloxane, cyclotentiloxane, cyclotentiloxane, cyclotentiloxane, cyclotentiloxane, cyclotentiloxane's methicone or mixtures of these. In some embodiments, the hydrophilic gel can be an alcoholic gel, where the gel has an alcohol content in a range of 20 to 90 percent by weight and in some cases, in a range of 60 to 85 percent in Weight.
[0087] In addition to polysiloxane macromolecules functionalized by diazeniodiolate and excipients, topical gels may also include at least
Petition 870200037495, of 03/20/2020, p. 33/73
25/53 minus an additional therapeutic agent such as antimicrobial agents, anti-acne agents, anti-inflammatory agents, analgesic agents, anesthetic agents, antihistamine agents, antiseptic agents, immunosuppressants, antihemorrhagic agents, vasodilators, wound healing agents, anti-biopellicent agents and mixtures thereof.
[0088] Examples of antimicrobial agents include penicillins and related medications, carbapenems, cephalosporins and related medications, erythromycin, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, sodium fusidate, lincomycin, clindamycin, rindamycin, macrindinine, rhodaminamine, macrolyin, rhodaminamine, macrolinine, rhodinamine, polymycinin, rhodamininine, polymycinin, rhodinamine, polymycinin, rhodaminamine, polymycinin, rhodaminamine, polymycinin, rhodaminamine, polymycinin. , tetracyclines, vanomycin, teicoplanin, streptogramins, anti-folate agents including sulphonamides, trimethoprim and combinations thereof and pyrimethylamine, synthetic antibacterials including nitrofurans, methenamine mandelate and methenamine hypurate, nitroimidazole, quinolones, fluoroquinolones, pyridine, ethanol, zinc, quinidone para-aminosalicylic (PAS), cycloserine, capreomycin, ethionamide, protionamide, thiacetazone, viomycin, eveminomycin, glycopeptide, glycliclycine, ketolides, oxazolidinone; imipenen, amicacin, netilmicin, fosfomycin, gentamicin, ceftriaxone, Ziracin, Linezolid, Synercid, Aztreonam and Metronidazole, Epiroprim, Sanfetrinem sodium, Biapenem, Dynemicin, Cefluprenam, Cefoselis, Lefen, Kosfem, Emilinam, Sulopenem, ritipenam acoxila, Ciclotialidine, micacocidin A, carumonam, Cefozopran and Cefetamet pivoxila.
[0089] Examples of topical anti-acne agents include adapalene, azelaic acid, benzoyl peroxide, clindamycin and clindamycin phosphate, doxycycline, erythromycin, keratolytics such as salicylic acid and retinoic acid (Retin-A ”), norgestimate, organic peroxides, retinoids such as isotretinoin and tretinoin, sodium sulfacetamide and tazarotene. The agents
Petition 870200037495, of 03/20/2020, p. 34/73
Particular anti-acne 26/53 include adapalene, azelaic acid, benzoyl peroxide, clindamycin (eg, clindamycin phosphate), doxycycline (eg, doxycycline monohydrate), erythromycin, isotretinoin, norgestimate, sodium sulfacetamide, tazarotene, tetretinate and acetretine. [0090] Antihistamine agents include diphenhydramine hydrochloride, diphenhydramine salicylate, diphenhydramine, chlorpheniramine hydrochloride, chlorpheniramine isotypendyl maleate, trypanamineamine hydrochloride, promethazine hydrochloride, methyldazine hydrochloride and others. Examples of local anesthetic agents include dibucaine hydrochloride, dibucaine, lidocaine hydrochloride, lidocaine, benzocaine, p-butylaminobenzoic acid ethyl ester hydrochloride 2- (dieethylamino), procaine hydrochloride, tetracaine, tetracaine hydrochloride, chloroprocaine hydrochloride oxyprocaine, mepivacaine, cocaine hydrochloride, piperocaine hydrochloride, diclonine hydrochloride and diclonine.
[0091] Examples of antiseptic agents include alcohols, quartenary ammonium compounds, boric acid, chlorhexidine and chlorhexidine derivatives, iodine, phenols, terpenes, bactericides, disinfectants including thimerosal, phenol, thymol, benzalkonium chloride, benzethonium chloride, chlorhexidine, povidone iodine, cetylpyridinium chloride, eugenol and trimethylammonium bromide.
[0092] Examples of anti-inflammatory agents include non-steroidal anti-inflammatory agents (NSAIDs); propionic acid derivatives such as ibuprofen and naproxen; acetic acid derivatives such as indomethacin; enolic acid derivatives such as meloxicam, acetaminophen; methyl salicylate; monoglycol salicylate; aspirin; mefenamic acid; flufenamic acid; indomethacin; diclofenac; aiclofenac; sodium diclofenac; ibuprofen; chetoprofen; naproxen; pranoprofen; fenprofen; sulindac; fenclofenac; clidanac; flurbiprofen; fentiazac; bufexamac; piroxicam; phenylbutazone; oxyphenbutazone; clofezone; pentazocine; mepirizole; thiaramide hydrochloride; steroids such as
Petition 870200037495, of 03/20/2020, p. 35/73
27/53 clobetasol propionate, betamethasone dipropionate, halbetasol propionate, diphlorasone diacetate, fluocinonide, halcinonide, amcinonide, deoxymethasone, acetonide triamcinolone, mometasone furoate, fluticasone proponate, fluticasone proponate, betamethasone propionate, betamethasone , fluocinolone acetonide, hydrocortisone valerate, prednicarbate, triamcinolone acetonide, fluocinolone acetonide, hydrocortisone and others known in the art, predonisolone, dexamethasone, fluocinolone acetonide, hydrocortisone acetate, predonisolone acetate, valetone acetate, acetone, acetone, acetone, acetate, acetonide, acetone betamethasone, flumethasone, fluorometholone, beclomethasone diproprionate, fluocinonide, topical corticosteroids and may be one of the lower potential corticosteroids such as hydrocortisone, hydrocortisone-21-monoesters (eg hydrocortisone-21-acetate, hydrocortisone-21-butyrortate, hydrocortisone-21-butyrortate na-21-propionate, hydrocortisone-21-valerate, etc.), hydrocortisone-17,21-diesters (e.g. hydrocortisone-17,21-diacetate, hydrocortisone-17-acetate-21-butyrate, hydrocortisone-17,21 -dibutyrate, etc.), alclomethasone, dexamethasone, flumetasone, prednisolone or methylprednisolone or can be a high-potency corticosteroid such as clobetasol propionate, betamethasone benzoate, betamethasone dipropionate, diflorasone diacetate, fluocinonide, fluocinonide, focetamine .
[0093] Examples of analgesic agents include alfentanil, benzocaine, buprenorphine, butorphanol, butamben, capsaicin, clonidine, codeine, dibucaine, encephalin, fentanyl, hydrocodone, hydromorphone, indometacin, lidocaine, levorfanol, meperidine, methadone, methadone, methadone, methadone, methadone, methadone, methadone, methadone, methadone, methadone, methadone, methadone, methadone, morphone, oxybutocaine, oxycodone, oxymorphone, pentazocine, pramoxin, proparacaine, propoxyphene, proximetacaine, sufentanil, tetracaine and tramadol.
Petition 870200037495, of 03/20/2020, p. 36/73
28/53
[0094] Examples of anesthetic agents include alcohols such as phenol; benzyl benzoate; calamine; chloroxylenol; diclonin; ketamine; menthol; pramoxin; resorcinol; troclosan; procaine medications such as benzocaine, bupivacaine, chloroprocaine; cincocaine; cocaine; dexivacaine; diamocaine; dibucaine; ethidocaine; hexylcaine; levobupivacaine; lidocaine; mepivacaine; oxetazaine; prilocaine; procaine; proparacaine; propoxicaine; pyrrocaine; risocaine; rhodocaine; ropivacaine; tetracaine; and derivatives, such as pharmaceutically acceptable salts and esters including bupivacaine HCl, chloroprocaine HCl, diamocaine cyclamate, dibucaine HCl, diclonine HCl, etidocaine HCl, levobupivacaine HCl, lidocaine HCl, mepivacaine HCl, pramoxin HCl, prilocaine , propoxycain HCl, ropivacaine HCl and tetracaine HCl.
[0095] Examples of anti-hemorrhagic agents include thrombin, phytonadione, protamine sulfate, aminocaproic acid, tranexamic acid, carbazochrome, sodium carbaxochrome sulfanate, rutin and hesperidin.
[0096] In addition to the polysiloxane macromolecules functionalized by diazeniodiolate, excipients and other therapeutic agents, the gels can also include other compounds that improve the organoleptic properties of the drug. Examples of such compounds include perfumes, pigments and colorants; chelating agents including but not limited to EDTA, EGTA, CP94, citric acid; preservatives including but not limited to quartenary ammonium compounds, such as benzalkonium chloride, benzethonium chloride, cetrimide, dekalinium chloride and cetylpyridinium chloride; mercurial agents, such as phenylmercuric nitrate, phenylmercuric acetate and thimerosal; alcoholic agents, for example, chlorobutanol, phenylethyl alcohol and benzyl alcohol; antibacterial esters, for example, parahydroxybenzoic acid esters; and other antimicrobial agents such as chlorhexidine, chlorocresol, benzoic acid and polymyxin.
[0097] Gels adjusted for particular therapeutic uses
Petition 870200037495, of 03/20/2020, p. 37/73
29/53
[0098] Wound healing occurs in several different stages and can happen in 0-12 months (or more). The stages of wound healing include:
(i) Coagulation (ii) Cell proliferation (iii) Formation of granulation tissue (iv) Epithelialization (v) Neovascularization or angiogenesis (vi) Contraction of injury (vii) Matrix deposition including collagen synthesis (viii) Tissue remodeling, including scar formation and scar remodeling
[0099] Nitric oxide can play a role in wound healing by a number of different mechanisms. First, extended exposure to low concentrations of nitric oxide can promote wound healing considering that nitric oxide acts as a signaling molecule in a number of wound healing cascades. In addition, nitric oxide can also play a role in relieving inflammation following damage. Modulation of inflammatory cytokines and inflammatory response cells through nitric oxide can significantly alter the healing stages of the above wound. In addition, injury and pain complications can be significantly reduced with topical administration of nitric oxide as an anti-inflammatory agent. In addition, nitric oxide can act as a broad-spectrum antimicrobial agent, particularly at relatively high concentrations. The antimicrobial effects of nitric oxide are wide-ranging and different types of wounds can be colonized with different wound pathogens (for example, gram negative bacteria, gram positive bacteria, fungi, etc.). In addition, some pathogens may be more sensitive to nitric oxide than other pathogens.
Petition 870200037495, of 03/20/2020, p. 38/73
30/53
In some embodiments, nitric oxide can act as the antimicrobial agent directly by killing planktonic bacteria and other organisms; directly killing the bacteria included in the bio-film and other organisms; indirectly the death of microorganisms through nitrosative / oxidative stress; relieving the biopellicle matrix; increasing the permeability of the drug across the microbial membranes; and / or preventing the recurrence of infection or the formation of a bio-film.
[00100] Therefore, in some embodiments, nitric oxide released from a particular medication can provide a particular therapeutic action, such as acting as a signaling molecule in a wound healing cascade, acting as an anti-inflammatory agent. inflammatory and / or current as an antimicrobial agent. As such, the particular diazeniodiolate-functionalized polysiloxane macromolecules and the gel composition can be cut to provide the appropriate NO release profile. Diazeniodiolates can be triggered to release nitric oxide by exposure to water or another proton source and an O2-protected diazeniodiolate can be triggered to release nitric oxide by light exposure, enzymatic action and / or pH adjustment.
[00101] The properties that may be involved through the choice of the pharmaceutically acceptable carrier include hydrophilicity and water absorption. Equilibrium moisture retention by a polymer can vary from 5 percent for certain aliphatic polymers to 2000 percent for hydrogels and superabsorbent polymers. Thus, in some embodiments, the drug may include a polymer that has a low equilibrium moisture retention in the range of less than 1 percent to 20 percent. In some embodiments, the drug may include a polymer that has a moderate equilibrium moisture retention in the range of 20 percent to 200 percent. Yet, in some embodiments, the drug may include a polymer that has a retention
Petition 870200037495, of 03/20/2020, p. 39/73
31/53 high balance humidity of 200 percent or more. Other excipients can also absorb water and / or be hydrophilic or hydrophobic. In some embodiments, the gel may also include water-absorbing excipients (for example, a SAP, a humectant and / or glycerol) if rapid release of NO is desired. If less NO release is desired, the gel may be more hydrophobic.
[00102] For topical medications that are gels or include monomers that can form gels in polymerization, as properties of the gel can be cut to affect the desired release NO characteristics. The properties of the gel that can be cut include:
(i) Mix vapor transfer rate (MVTR)
[00103] The MVTR can be adjusted on the gel to match the requirements of a macromolecule that releases reactive NO of water in a gel yet maintains MVTR suitable for the desired damage or injury area. The gels that maintain a moist wound layer are called occlusive. A great MVTR maintains a moist wound environment that activates debridization enzymes and development factors that promote wound healing. Occlusive gels can also act as a barrier towards exogenous microbes, thus preventing infection. Occlusion is defined by an MVTR through the wound lining below 840 g / m ² for 24 hours of the period.
(ii) Biodegradability / Bioabsorbability
[00104] Biodegradability refers to the property of the gel to break down into lower molecular weight components under physiological conditions. Bioreabsorbability refers to the property by which the wound dressing can break in the lower molecular weight segments and the segments are completely removed from the body without any biological.
(iii) Oxygen permeability
[00105] The adequate oxygen level facilitates neovascularization, helps
Petition 870200037495, of 03/20/2020, p. 40/73
32/53 in collagen synthesis and can prevent or minimize microbial infection of the wound. Due to the damaged vasculature, it may be a low oxygen tension in the wound layer, leading to hypoxia and anaerobic metabolism that can delay the healing process. Gels can be oxygen permeable as long as the wound receives adequate topical oxygen for healing.
(iv) Nitric oxide permeability
[00106] The gel may have adequate permeability towards nitric oxide such that the nitric oxide generated by the macromolecules that release NO is available in the wound layer at a desired therapeutic rate. Hydrophilic materials typically have a lower NO permeability towards nitric oxide as compared to hydrophobic materials. The NO permeability of the gel can be matched to a macromolecule release kinetics that releases NO and the rate of water absorption by the polymer, in order to provide for the optimal release of NO from the gel.
(v) Expansion capacity
[00107] The ability of the gel to swell without dissolving in contact with the wound moisture is beneficial in high sweating wounds. The gel can serve to inhibit excess moisture which can otherwise cause the wound to macerate and noxious odor.
(vi) Biocompatibility
[00108] The gel can be biocompatible, non-toxic and non-irritable.
(vii) Ionic character
[00109] The ionic character of the gel can affect the surface energy and biocompatibility of the gel. The ionic character of the gel can be quantified by measuring the zeta potential of the wound dressing material under physiological conditions. Surfaces with highly positive or highly negative zeta potential may be unwanted as they may have an anti or pro coagulant effect on the wound and may increase surface energy.
Petition 870200037495, of 03/20/2020, p. 41/73
33/53
[00110] In some embodiments of the invention, at least one property of the gel and / or at least one property of the diazeniodiolate functionalized polysiloxane macromolecules can affect the wet absorption / retention, the wet vapor transfer rate (MVTR), oxygen permeability, NO permeability, biodegradability / bioabsorbability, biocompatibility and ionic character. The total amount of nitric oxide stored in the macromolecules, the hydrophobicity / hydrophilicity of the macromolecules and the gel and the biodegradability / bioresorbability of the macromolecules and the gel control of the intrinsic pH, the wet equilibrium absorption and regulate the diffusion of oxygen in the gel to modulate nitrosative intermediates or the appearance of nitrite / nitrate by-products. The formation of the polymer gel can also trap the functionalized diazeniodiolate macromolecules and prevent or minimize their penetration into the wound layer.
[00111] In some embodiments of the invention, the gel is a hydrophobic and non-aqueous gel. The use of an anhydrous and hydrophobic gel can monitor or prevent the release of NO during storage of the formulation. Hydrophobic, non-aqueous compositions may also allow for the lower diffusion of water required to initiate the decomposition of diazeniodiolate and subsequent release of NO to an injury. As well, the gel can be useful for the treatment of acute and / or chronic injuries.
[00112] In some embodiments of the invention, the non-aqueous, hydrophobic gel base may be a silicone gel. In particular the embodiments, the silicone gel includes cyclomethicone in a concentration in a range of 5 to 30 weight percent and cross-linked polydimethylsiloxane in a concentration in a range of 65 to 85 weight percent. In other embodiments, the non-aqueous, hydrophobic gel base includes polyol in a concentration in the range of 67 to 76 weight percent; electrolyte in a concentration in the range of 0.1 to 2.5 weight percent; silicone
Petition 870200037495, of 03/20/2020, p. 42/73
34/53 polyol in a concentration ranging from 20 to 30 weight percent; and volatile silicone based solvent in a concentration in a range of 2.5 to 13 weight percent. In other embodiments, the non-aqueous, hydrophobic gel base includes petrolatum in a concentration in the range of 60 to 70 weight percent; dimethicone in a concentration in a range of 5 to 10 weight percent; and solvent based on volatile silicone.
[00113] In addition, in other embodiments, the non-aqueous, hydrophobic gel base includes a silicone elastomer in a concentration in a range of 60 to 70 weight percent; and volatile organic solvent in a concentration in a range of 5 to 10 weight percent and in other embodiments, the non-aqueous, hydrophobic gel base includes silicone elastomer in a concentration in a range of 70 to 80 percent in Weight; and volatile organic solvent in a concentration in a range of 15 to 20 weight percent.
[00114] In addition, in some embodiments, the resulting non-aqueous, hydrophobic gel containing diazeniodiolate functionalized polysiloxane macromolecules may have an MVTR below 840 g / m ² for a period of 24 hours.
[00115] Any suitable polyol can be used in the compositions described in this. However, examples of polyols include 1,2-ethanediol, 1,3propanediol, 1,4-butanediol, 1,6-hexanediol, 1,5-pentanediol, 1,10decanediol, 2-methyl-1,3-propanediol, 2- methyl-2-butyl-1,3-propanediol, 2,2dimethyl-1,3-propanediol, 2,2-dimethyl-1,4-butanediol, 2-ethyl-2-butyl-1,3propanediol, neopentyl glycol hydroxypivalate , diethylene glycol and triethylene glycol,
[00116] Any suitable electrolyte can be used. However, examples of electrolytes include sodium chloride, potassium chloride, calcium chloride and magnesium chloride.
[00117] Any suitable silicone polyol can be used. However
Petition 870200037495, of 03/20/2020, p. 43/73
35/53 examples of silicone polyols include copolyol dimethicone, copolyol laurylmethylone, copolyol cetyldimethicone, SilSense® SW-12 dimethicone copolyol ester, SilSense® Copoliol-1 Silicone, Lambent waxes, PEG / PPG-4/12 dimethicone, Bis- PEG / PPG-20/20 dimethicone, PEG / PPG-20/6 dimethicone, PEG / PPG-14/4 dimethicone and PEG / PPG-20/20 dimethicone.
[00118] Any suitable silicone based solvent can be used. However, examples of silicone-based solvents include cyclomethicone and dimethicone.
[00119] Any suitable silicone elastomer can be used. However, examples of silicones elastomer include dimethicone cross-polymer, dimethicone / vinyl dimethicone cross-polymer, cyclopentasiloxane / dimethicone cross-polymer, cetearyl / dimethicone cross-polymer, Wacker Belsil RG-100, ST-Elastomer 10 and trimethylsiloxycilate / cross-polymer thymethicone.
[00120] In some embodiments, the gel includes polysiloxane macromolecules functionalized by diazeniodiolate, caprylic or capric triglyceride in a concentration in a range of 25 to 55 weight percent; fumigated silica in a concentration in a range of 4 to 8 weight percent; cyclomethicone in a concentration in a range of 5 to 20 weight percent; optionally, isopropyl myristate in a concentration in a range of 10 to 85 weight percent; and optionally, mineral oil in a concentration in a range of 10 to 90 weight percent.
[00121] In some embodiments, the topical gel includes polysiloxane macromolecules functionalized by diazeniodiolate and a hydrophilic gel base. In particular the embodiments, the concentration of the polysiloxane macromolecules functionalized by diazeniodiolate is in the range of 0.1 to 2 weight percent. In addition, in particular embodiments, the gel includes polysiloxane macromolecules functionalized by diazeniodiolate, an ethyl cellulose polymer in a
Petition 870200037495, of 03/20/2020, p. 44/73
36/53 concentration in a range of 8 to 20 weight percent; and a fatty acid ester in a concentration in a range of 60 to 90 weight percent.
[00122] In some embodiments, the gel includes polysiloxane macromolecules functionalized by diazeniodiolate, polyethylene glycol in a concentration in a range of 15 to 60 weight percent; and propylene glycol in a concentration ranging from 30 to 80 weight percent; cross-linked polyacrylic acid in a concentration in the range of 0.5 to 4.0 weight percent; optionally, 2-amino-2-methyl propanol in a concentration in a range of 0.05 to 0.15 weight percent; optionally, glycerin in a concentration in a range of 15 to 25 weight percent; and optionally, niacinamide in a concentration in the range of 0.25 to 1.25 weight percent.
[00123] In some embodiments, the gel includes polysiloxane macromolecules functionalized by diazeniodiolate, benzyl alcohol in a concentration in a range of 10 to 30 weight percent; isopropyl alcohol in a concentration ranging from 30 to 75 weight percent; HPC in a concentration in a range of 0.75 to 2.5 weight percent; optionally, 2-amino-2-methyl propanol in a concentration in a range of 0.05 to 0.15 weight percent; optionally, trolamine in a concentration in the range of 0.1 to 1.5 weight percent; optionally, fumigated silica at a concentration in the range of 1.0 to 7.0 weight percent; and optionally, niacinamide in a concentration in the range of 0.25 to 1.25 weight percent.
[00124] In some embodiments of the invention, polysiloxane macromolecules functionalized by diazeniodiolate in the hydrophilic gel can have a separation coefficient of octanol / water in a range of -2 to 0. In some embodiments of the invention, the macromolecules of polysiloxane functionalized by diazeniodiolate in the non-aqueous, hydrophobic gel may have an octanol / water separation coefficient
Petition 870200037495, of 03/20/2020, p. 45/73
37/53 in a range of 0.1 to 7.
Methods of treating wounds and skin diseases
[00125] In some embodiments of the invention, provided are methods of treating a wound by applying a topical gel according to an embodiment of the invention. Such methods can be used in combination with any other known methods of treating the wound, including the application of other therapeutic agents, such as those that have anti-inflammatory, pain relief, immunosuppressive, vasodilator, wound healing and / or healing properties. antibiopellicle formation. For the methods used in this, additional therapeutic agents and methods can be used before, concurrently with or after application with a gel according to embodiments of the invention. Gels according to the embodiments of the invention can also be used in any combination with any wound dressing known to the person skilled in the art.
[00126] In some embodiments of the invention, the topical gel provided in this can be used in conjunction with at least one agent that can disrupt the biopellicle macrostructure before or in conjunction with the application of a wound dressing. In some embodiments, the anti-bio-film agent can disrupt the extracellular matrix of the bio-film. Examples of anti-biopellicent agents that can act in this way include lactoferrin, periodate, xylitol, DNase, protease, an enzyme that degrades extracellular polysaccharides. In some embodiments of the invention, the formulation of the anti-film agent is acidic to promote DNase enzyme activity (e.g., mammalian DNases such as DNase II) and the acidic conditions simultaneously can also enhance the release of the NO rate to from the diazeniodiolate macromolecules. In some embodiments, the protease may include at least one of the proteinase K, trypsin, Pectinex Ultra SP (PUS) and pancreatin. In some
Petition 870200037495, of 03/20/2020, p. 46/73
38/53 embodiments, enzymes that degrade extracellular polysaccharides can include N-acetylglucosaminidases (eg dispersin B).
[00127] In some embodiments of the invention, the antibiopellicle agent can act by affecting the transcriptional, translation and / or post-translation regulation of the sensitizing genes of the members or products of the genes in the infected organisms. For example, anti-biopellicent agents can include at least one of hamelitanin, cyclic di-GMP or sublethal concentrations of nitric oxide.
[00128] Anti-biopellicent agents can also act by other mechanisms. For example, the anti-biopellicent agent can cause the infected organism to transition from a sessile state to a metabolically active state. As another example, the anti-biopellicle agent can act by causing the infected organism to transition from a non-mobile state to a mobile phenotype.
[00129] In some embodiments of the invention, the topical gel provided herein can be used in conjunction with the wound debridement procedure. For example, in some embodiments, injuries can first be treated with a debridement procedure; and then a gel according to an embodiment of the invention can be applied to the debridized wound. Medicaments according to embodiments of the invention can increase the wound healing rate, decrease inflammation and / or exert and antimicrobial effect. Wound dressings according to embodiments of the invention can be used in conjunction with any suitable debridization procedure. For example, the debridization procedure can be selective or non-selective.
[00130] In some embodiments, the debridization procedure may include at least one of the surgical processes,
Petition 870200037495, of 03/20/2020, p. 47/73
39/53 enzymatic, autolytic, precise, mechanical and biological. Any suitable surgical method can be used, but in some embodiments, the surgical method involves a surgical cut in addition to the non-viable tissue in the wound. Any suitable enzymatic method can be used, but in some embodiments, the enzymatic method may involve the use of one or more proteases, their required cofactors and optionally any enhancing agents, to digest the non-viable tissue in the wound. Exemplary proteases include trypsin, papain or other plant-derived proteases and collagenase. Any suitable autolytic method can be used, but in some embodiments, the autolytic method involves maintaining a moist wound environment in order to promote the breakdown of non-viable tissue by enzymes that are naturally produced by the body. Any suitable mechanical method can be used, but in some embodiments, mechanical methods include wet to dry gauze, irrigation, pulsating wash, water swirl therapy and / or low frequency ultrasound. Any suitable severe method can be used, but in some forms of realization, the severe method involves cutting beyond the non-viable tissue by qualified clinical staff (for example, RN or nurse). Any suitable biological method can be used, but in some embodiments, the biological method involves the use of fly larvae that selectively digest non-viable tissue in the wound. This debridement method can be used alone or in combination.
[00131] After the wound is debrided, a topical gel according to an embodiment of the invention can be applied. Additional processes can be performed and therapeutic agents can be applied. For example, after debridement, an anti-film agent can be applied to the wound before or in conjunction with the application of the topical gels provided therein. Exemplary anti-biopellicent agents include acetylsalicylic acid (aspirin), cyclic di-GMP, lactoferrin, gallium, selenium,
Petition 870200037495, of 03/20/2020, p. 48/73
40/53 as described above. Other compounds, such as hamamelitanin (amaelia extract), arginine and c-di-GMP, can also be applied.
[00132] The gels can be applied to a patient in any suitable way, such as, for example, rubbing, dispersing or placing the gel on the wound or a wound dressing to be in contact with the wound. In some embodiments, the topical gel can be administered to a wound through the spray release. A non-aqueous release propellant can be used by water on sensitive diazeniodiolate functionalized polysiloxane macromolecules. In addition, in some embodiments, particular components of the gels can be separated at the same point before the drug is applied. For example, the diazeniodiolate polysiloxane macromolecule can be stored separately from an aqueous or propellant component until application (for example, by spraying or applying a gel). In some embodiments, the diazeniodiolate polysiloxane macromolecule may be combined with an aqueous constituent prior to application of the diazeniodiolate polysiloxane macromolecule and in some embodiments, an aqueous constituent may be applied sequentially to the wound layer.
[00133] Gels according to some embodiments of the invention can also be used to treat burns. A major goal in the treatment of burns is the resurgence and increase in fluid levels because of the significant loss of water from the body when the function of the skin barrier is compromised. Topical nitric oxide formulations that enhance skin barrier function can not only restore this critical function for maintaining patient vitality but also prevent infection of patients with burn injuries as the compromised barrier function also creates a pathway
Petition 870200037495, of 03/20/2020, p. 49/73
41/53 easy for microbial contamination and colonization.
[00134] Hydrophobic gels in particular can be advantageous to use in the treatment of burns. The non-aqueous, hydrophobic gel can create an occlusive environment in burn wounds and thus prevents desiccation and create a moist wound environment. In some embodiments, for the treatment of burns, the polysiloxane macromolecules functionalized by diazeniodiolate can be loaded into such a gel in different concentrations during different times during the curing process. For example, to avoid infection, a gel can be applied to one that has a NO loading in a range of 10 pmol NO / g of gel to 1 mmol NO / g of gel. During the last phases of tissue remodeling, for example, several weeks after damage, nitric oxide can be loaded in concentrations in a range of 1 nmol NO / g of gel to 10 pmol NO / g of gel to facilitate healing and remodeling of the matrix. The moist wound environment created by occlusive hydrophobic gels capable of releasing nitric oxide from polysiloxane macromolecules functionalized by diazeniodiolate which is otherwise unexpectedly stable at room temperature in a non-aqueous gel matrix. The diffusion of water throughout the gel matrix in this way controls the rate of decomposition of proton-initiated diazeniodiolate, favoring the faster macromolecular compositions of diazeniodiolate polysiloxane, such as those with an average aqueous life in the range of 0.5 minutes to 10 minutes. A quick release NO profile for hydrophobic gel matrices can enable these levels of antimicrobial NO release. However, for the sustained release of nitric oxide from the gel every few hours, the hydrophobic matrix bound with a slower degradation diazeniodiolate functionalized polysiloxane macromolecule can produce a unique NO release signature that exhibits a flat release profile.
[00135] Gels according to embodiments of the invention can
Petition 870200037495, of 03/20/2020, p. 50/73
42/53 be used to treat acne. Lipophilic polysiloxane macromolecules functionalized by diazeniodiolate can target the pilosebaceous gland and penetrate the sebum-rich environment, for example, as the potential treatment against acne vulgaris. As described above, gels according to the embodiments of the invention can include other therapeutic agents. In the case of acne treatment, the gels can include other anti-acne agents such as retenoids, such as those described herein. In addition, agents such as retenoids can be used in conjunction (before, concurrently or after) with a gel according to an embodiment of the invention.
[00136] Gels according to embodiments of the invention can be used to treat other skin diseases, by means of antimicrobial action, anti-inflammatory action, or any other mechanism. For example, topical gels described in this can be used to treat other skin conditions such as impetigo, psoriasis, tinea pedis, onychomycosis and others.
[00137] Suitable patients will be treated with a gel according to an embodiment of the invention include, but are not limited to, mammalian and avian patients. Mammals of the present invention include, but are not limited to, canines, felines, cattle, goats, horses, sheep, porcines, rodents (e.g., rats and mice), lagomorphs, primates, humans and others and mammals in utero. Any mammalian patient in need of treatment according to the present invention is suitable. Human patients are preferred. Human patients of both sexes and at any stage of development (i.e., newborn, child, youth, adolescent, adult) can be treated in accordance with the present invention.
[00138] Illustrative aviaries in accordance with the present invention include chickens, ducks, turkeys, geese, quail, pheasants, ratites (for example, ostrich) and domestic birds (for example, parrots and canaries) and
Petition 870200037495, of 03/20/2020, p. 51/73
43/53 birds in ovo.
[00139] The invention can also be performed on animal patients, particularly mammalian patients such as mice, rats, dogs, cats, cattle and horses for veterinary purposes and for the evaluation of the drug and drug development purposes.
EXAMPLES
Example 1: Synthesis of Macromolecules that release NO
[00140] FIG. 1 illustrates the covalent storage of nitric oxide in the N-methylaminopropyltrimethoxysilane aminosilane as a diazeniodiolate NO donor, followed by co-condensation with an alkoxysilane of structure, tetraethoxysilane, to form the composition Nitricil ™ 70. Such a macromolecule that releases NO may be incorporated in medicines according to some embodiments of the invention.
Example 2: Efficacy of Nitricil ™ -70 against gram-negative and representative gram-positive bacteria
[00141] The antimicrobial efficacy of dry powder Nitricil ^TM -70 was evaluated against gram-positive organisms resistant to the representative multiple drug (HA-MRSA, ATCC 33591, type III SCCmec) and gram-negative (P. aeruginosa, ATCC 15442) using the ASTM E 2315 test method. Various concentrations of NJ070 particles were incubated, in duplicates, with P. aeruginosa (See FIG. 2A) or HA-MRSA (See FIG. 2B) at 37 ° C in a 1: 1000 dilution of Tripticase soy broth. At the indicated time points, an aliquot of each culture was serially diluted and placed to quantify the remaining viable colony formation units (CFU / ml).
[00142] Nitricil ™ 70 solid kills both P. aeruginosa and MRSA in a time and dosage-dependent manner, with 99.9 percent P. aeruginosa death reached at earlier time points and lower concentrations than are required by HA -MRSA. These data suggest that
Petition 870200037495, of 03/20/2020, p. 52/73
44/53
Nitricil ™ is active against both gram positive and gram negative bacteria, but can be effective against gram negative bacteria at lower dosages.
Example 3: Effectiveness of a gel based on Nitricil ™ 70 silicone on full thickness excisional wounds in an infected rat animal model
[00143] A non-aqueous, hydrophobic NO-releasing gel was formulated using 75 percent Dimethicone / Vinyl cross-dimethicone polymer and ~ 25 percent cyclomethicone co-solvent as a viscosity modifier. Nitricil ™ -70 in a weight of 24 mg (0.1% w / w of the final gel load) or 240 mg (1.0% w / w of the final gel load) was dispersed in 6 ml of cyclomethicone and sonified to provide a homogeneous particle suspension based on the similarity of the silicone solvent and exterior of the co-condensed siloxane particles. The concentrations of the components are listed below in TABLE 1. The Nitricil ™ suspension was then combined with dimethicone gel in a 1: 3 ratio to provide the finished compositions for the animal test. The empty vehicle contains only dimethicone and cyclomethicone co-solvent absent of any macromolecules that release NO.
TABLE 1
NitricilTM 70 Dimethicone cross polymer Cyclomethicone 0.1% 75% 24.9%
NitricilTM 70 Dimethicone cross polymer Cyclomethicone 1.0% 75% 24.0%
[00144] Two excisional wounds of a total thickness of 2 x 2 cm were made on the back of the nude rats crossing a total of 36 animals broken in the groups shown in TABLE 2.
TABLE 2
Group # of animals Test article Generation of the day 0 injury model Inoculation Treatment Day 0 model generation ME &NXDay 1 ME &NXDay 3 ME &NXDay 5 ME &NXDay 7 ME &NXDay 9 Total diary w / TA with pseudomonas THE 8 Control Two 2 x 2 cm diary Day (0) 8 0 2 2 2 2 8 B 8 Empty vehicle on the back of diary Day (0) 8 0 2 2 2 2 8
Petition 870200037495, of 03/20/2020, p. 53/73
45/53
Ç 8 0.1% gelfrom Nitricila mouse diary Day (0) 8 0 2 2 2 2 8 D 8 1.0% gelfrom Nitriciladiary Day (0) 8 0 2 2 2 2 8 AND 4 No treatmentdiary Day (0) 4 4 0 0 0 0 4 TOTAL 36 36 4 8 8 8 8 36 Balance after each euthanasia 32 24 16 8 0
[00145] Immediately following the wounds, the wounds were caused with 100 μL of an inoculum 107 of P. aeruginosa and covered with transparent biocclusive dressings (Johnson and Johnson) for hours to develop the mature P. aeruginosa bio-film. The treatment with 200 mg of Blank gel, 0.1 weight percent and 1.0 weight percent of silicone gels loaded with Nitricil ^TM started on day 1 and was repeated once a day for the duration of the study. The thin-film occlusive dressings were also replaced following each treatment. On day 3, two animals from each group were euthanized and 8 mm perforated biopsies were taken from the center of each wound, homogenized in sterile saline and placed to determine the number of colonies per gram of tissue. Referring to FIG. 3, untreated control wounds and wounds treated by empty vehicles exhibit 2.5 x 10 ⁸ and 9.0 x 10 ⁸ CFU / g of tissue respectively. However, 0.1 percent of gel loaded by Nitricil ^TM 70 demonstrates a> 99 percent reduction in the number of P. aeruginosa per g of tissue with an average value of 1.37 x 106 CFU / g of tissue crossing the 4 samples taken. 1.0 percent gel also showed a substantial reduction compared to controls at 6.84 x 106 CFU / g tissue.
[00146] Photographs of the wound were taken with each application of topical gel and before necropsy. Quantitative measurements of the wound area for each treatment group were performed using the scale bar provided in each photograph. The wound area (cm) was measured by all available wounds and converted to the percentage of wound closure when compared to the initial wound area for each individual wound. The data for day 3 and day 9 are shown in FIG. 4.
Petition 870200037495, of 03/20/2020, p. 54/73
46/53
[00147] On day 3, 0.1 percent of the silicone gel carried by Nitricil ™ showed a dramatic intensification, close to 25 percent of the major wound closure compared to all other treatment groups. A series of images for all treatment groups from day 0 (injury) until the end of the study on day 9 are shown in FIG. 5. [00148] Example 4: Other hydrophobic formulations (Prophetic)
A: Non-aqueous silicone based emulsion • Aqueous formulations containing Nitricil ™ in the form of a cream that can be applied to the wound layer.
• Prepared by mixing phase A, which includes a polyol such as propylene glycol (67 weight percent to 76 weight%), an electrolyte such as NaCl (0.5 weight%) and the active agent Nitricil ™ (1% 10% by weight) with phase B, which includes a silicone based polyol such as dimethicone copolyol (20 to 30% by weight) and a volatile silicone based solvent such as cyclomethicone (2.5% by weight) to 10% by weight).
• Electrolytes such as NaCl can be added to formulations to stabilize the emulsion.
• Phase A and phase B are heated separately to 80 ° C under nitrogen to preserve the stability of the NO diazeniodiolate donor and mixed at 800 RPM using a stirring deflector. Cooled and stored at room temperature.
[00149] The formulation concentrations, shown in% (w / w), are given in TABLE 3.
TABLE 3
Phase A Phase B Propylene glycol NaC1 Nitricil ™ Dimethicone copliol Cyclomethicone 76% 0.5% 1% 20% 2.5%
B: Silicone based ointment • Non-aqueous ointment based on additional Petrolate.
• Includes a volume of Petrolato (60% to 70%) in addition to
Petition 870200037495, of 03/20/2020, p. 55/73
47/53 dimethicone (mixture of Dimethicone 20, 5% to 10%), where Nitricil ™ was mixed (1% to 10%); a volatile silicone solvent, such as cyclomethicone, is used for viscosity adjustment (10% to 20%).
• Dimethicone 20 blend provides relief from swelling and can also provide a smooth skin feel.
• Under continuous agitation, Nitricil ™ disperses in cyclomethicone at room temperature; add Dimethicone 20 mixture at room temperature, followed by the addition of Petrolat heated separately to 75 ° C.
[00150] The formulation concentrations, shown in% (w / w), are provided in TABLE 4.
TABLE 4
Petrolato Dimethicone mix20 Phase B Cyclomethicone Nitricil ™ 65% 5% 20% 10%
C: ST elastomer based on non-aqueous gel • Non-aqueous gel including a silicone elastomer (70% at
%) mixed with a volatile organic solvent (15% to 20%) containing Nitricil ^TM (1% to 10%) • May contain isopropyl myristate as an emollient (0.5% to 1%) • Dissolve isopropyl myristate in cyclomethicone, disperse Nitricil ^TM , add ST 10 Elastomer under continuous mixing.
[00151] Formulation concentrations, shown in% (w / w), are given in TABLE 5.
TABLE 5
Nitricil ™ ST-cyclomethicone 5 ST 10 elastomer Isopropyl myristate 5% 19% 75% 1%
D: Non-aqueous gel based on Wacker Belsil • Non-aqueous gel containing Nitricil ^TM (1% to 10%) silicone elastomer, Wacker Belsil RG-100 (60% to 80%), mixed with
Petition 870200037495, of 03/20/2020, p. 56/73
48/53 a volatile organic silicone solvent (15% to 25%) to control viscosity.
• Contains glycerol as an emollient (1% to 2%) • Dissolve glycerol in cyclomethicone, disperse Nitricil ™, add Elastomer ST 10 with continuous mixing.
[00152] Formulation concentrations, shown in% (w / w), are provided in TABLE 6
TABLE 6
Nitricil ™ ST-cyclomethicone 5 Wacker Belsil RG-100 Glycerol 2% 18% 78% 2%
Example 5: Antimicrobial activity of a hydrophilic gel based on Nitricil ™ 70 against MRSA bio-films
[00153] A hydrophilic NO release gel was formulated using glycerol as the base. Carbopol 940 was used as a rheology modifier. Briefly, Carbopol 940 was dissolved in glycerol at a concentration of 0.5% (w / v) by stirring overnight 0.1 g of Carbopol 940 in 20 ml of glycerol at 50 ° C. In a separate container, 200 pl of triethanolamine was added to 10 ml of glycerol, to adjust the pH to 11.0.
[00154] Nitricil ^TM -70 in a weight of 18.93 mg (1% w / w final gel loading) or 189.3 mg (10% w / w final gel loading) was dispersed in 1 ml of glycerol at pH 11.0, using a stirring deflector at 500 RPM. Half a milliliter of 0.5% Carbopol 940 solution was added to the Nitricil ^TM -70 dispersion under continuous stirring at 500 RPM. The resulting viscous gel was transferred to a 3 ml polypropylene syringe. The pH of the gel was measured to be 7.0.
[00155] Formulation concentrations, shown in% (w / w), are provided in TABLE 7
TABLE 7
Nitricil Carbopol 940/941 Glycerol 1% 0.13% 98.87%
Nitricil Carbopol 940/941 Glycerol
Petition 870200037495, of 03/20/2020, p. 57/73
49/53
10% 0.13% 89.87%
[00156] The NO release of the gel was measured by weighing a smaller amount of gel (2.8 mg) in the chemiluminescent nitric oxide analyzer, as shown in FIG. 6.
[00157] MRSA colony biopellets were developed on UV sterilized 25 mm polycarbonate filters (0.22 μηι) as previously described (Anderl et al 2000, Rani et al 2007). Briefly, an overnight culture of S. aureus ATCC 33591 was diluted to OD600 of approximately 0.1. Ten microliters of the diluted culture was stained in the center of a latent polycarbonate filter on a tryptic soy agar plate. The biopellicles were developed for two days at 37 ° C, with a transfer on a new TSA plate after 24 hours. At the beginning of the experiment, each filter was transferred to an individual reservoir in a 6-reservoir plate. The gel formulations (0.1 ml) were added to the drops on the top of each bio-film (three bio-films per treatment) without interrupting the structure of the bio-film. The plates were incubated outside the humidified box (37 ° C, 24 hours). After 24 hours, Letheen broth (1 ml) was used to wash each reservoir and then added, together with each filter, to 9 ml of Letheen broth in 50 ml conical. The conics were sonified (1 min) and subjected to swirling (1 min). The resulting bacterial suspension was seriously diluted and placed to obtain colony counts. The results are shown in TABLES 8 and 9.
TABLE 8: Raw data for Nitricil ™ 70 hydrophilic gel versus MRSA bio-films
Sample Id Repetition Time CFU / ml CFU log % Red Log Red No treatment 1 24 h 1.46E + 09 9.16 -26.8 -0.12 No treatment 27.98E + 08 8.90 30.6 0.15 No treatment 31.19E + 09 9.08 -3.8 -0.03 HG-CONTROL -003 1 24 h 1.63E + 08 8.21 85.8 0.84 HG-CONTROL -003 21.68E + 08 8.23 85.4 0.82 HG-CONTROL -003 31.60E + 08 8.20 861 0.84 01-00009-002-HG-01-0001 1 24 h 1.40E + 06 6.15 99.88 2.90 01-00009-002-HG-01-0001 21.12E + 06 6.05 99.90 3.00 01-00009-002-HG-01-0001 33.32E + 06 6.52 99.7 2.53 01-00009-002-HG-10-0001 1 24 h 1.00E + 03 3.00 99.99991 6.0
Petition 870200037495, of 03/20/2020, p. 58/73
50/53
01-00009-002-HG-10-0001 21.00E + 03 3.00 99.99991 6.05 01-00009-002-HG-10-0001 3 3.10E + 03 3.49 99.9997 5.56
TABLE 9: Summary of data for Nitricil ™ 70 hydrophilic gel versus MRSA bio-films
Test article: Time AverageCFU / ml Lg CFU. % Red Log Red No treatment 24 h 1.15E + 09 9.05 0.00 0.00 HG-CONTROL -003 24 h 1.64E + 08 8.21 85.8 0.83 01-00009-002-HG-01-0001 24 h 1.95E + 06 6.24 99.8 2.81 01-00009-002-HG-10-0001 24 h 1.70E + 03 3.16 99.9999 5.88
Example 6: Other hydrophilic formulations (Prophetic)
[00158] A: Non-aqueous gel based on Ethocel • Non-aqueous gel including ethyl cellulose polymers dissolved in Dicaprilat / Propylene Glycol Prylate (Migliol).
• Ethyl cellulose polymers are used as pharmaceutical excipients, tablet binders, etc. and solvent Migliol has inherent emollient properties due to its vegetable triglyceride base.
• Ethocel Std 7 FP Premium polymers (11-16%), Ethocel Std 10 FP Premium (11-16%), Ethocel Std 100 FP Premium (7 to 12%) will be used. These concentrations are lower by 100 FP due to their longer chain length. The migliol solvent 840 will be used (80% to 85%). The concentration of Nitricil will be varied from 1 to 10%.
[00159] Formulations with various Ethocel polymers are shown in TABLES 10-12.
Petition 870200037495, of 03/20/2020, p. 59/73
51/53
Table 10: Ethocel Std 7 FP Premium
Nitricil ™ Ethocel St 7 FP Miglyol 840 1% 16% 83% 2% 14% 84% 5% 12.5% 82.5% 10% 11% 79%
Table 11: Ethocel Std 10 FP Premium
Nitricil ™ Ethocel St 10 FP Miglyol 840 1% 16% 83% 2% 14% 84% 5% 12.5% 82.5% 10% 11% 79%
Table 12: Ethocel Std 100 FP Premium
Nitricil ™ Ethocel St 100 FP Miglyol 840 1% 12% 87% 2% 10% 88% 5% 8.5% 86.5% 10% 7% 83%
Example 7: Nitric oxide stability as a function of gel excipients
[00160] A series of topical gels have been formulated for containing silica particles that release nitric oxide in weight percentages ranging from 0.1% to 2.0% w / w and the percentage of nitric oxide recovered from gel prototypes formulated was measured using nitric oxide chemiluminescence. Not all excipient combinations were able to obtain the donor stability of diazeniodiolate NO (TABLE 16). Unexpectedly, a series of topical gels containing diazeniodiolate modified silica that exhibit stability at room temperature have been recovered.
Petition 870200037495, of 03/20/2020, p. 60/73
52/53
Table 13: Gels that comprise Cab-O-Sil as the thickness agent (%
E / B)
ID Nitricil ^TM CCTG Isopropyl myristate Cab0-Sil M5P Cyclomethicone Mineral oil PPG-15 THE 0.1% 50.4% 42.0% 7.5% B 0.1% 7.5% 10% 814%Ç 1.0% 51.0% 42.0% 6.0% D 1.0% 6.0% 13.0% 80.0%AND 1.0% 49.5% 42.0% 7.5% F 1.0% 7.5% 10.0% 82.5%G 1.0% 8.0% 10.0% 82.0%H 1.0% 29%5.0%49.0% 16.0% I 1.0% 29%7.0%47.0% 16.0% J 1.0% 52%5.0% 13% 13.0% 16.0%
Table 14: Gels that include Carbopol 980 as the thickening agent (% w / w)
ID Nitricil ™ PEG300 Propylene glycol Carbopol980 Glycerin AMP Niacinamide K 0.1% 20.0% 62.1% 0.65% 17.0%, 0.10%L 0.1%76.0% 0.80% 23.0% 0.10%M 1.0% 57.1% 41.0% 0.80%0.10%N 1.0% 56.8% 41.0% 1.0%0.15%THE 1.0% 55.7% 41.0% 1.0% 1.25%
Table 15: Gels based on alcohol (% w / w)
1D Nitricil ™ Benzilic alcohol IPA HPC AMP Niacinamide Trolamine Cab-O-Sil M5P2.0% 25.0% 71.0% 2.0%2.0% 25.0% 69.0% 1.75%1.25% 1.0% 2.0% 25.0% 68.0% 1.0% 1.0% 3.0% s 2.0% 25.0% 71.1% 1.75% 0.1%
Table 16:% nitric oxide remaining following the initial formulation of the excipients as a measure of stability performance (ND = not determined)
ID % of remnant NOID % of remnant NOID % of remnant NO THE NDH 97%THE 59% B NDI 71%P 70% Ç 74%J 93%Q 70% D 100%I NDR 72% AND 100%L 15%s ND F 82%M 83% G 94%N 54%
Petition 870200037495, of 03/20/2020, p. 61/73
53/53
[00161] Figure 7 shows the NO release curves that show the change in the kinetic profile as a function of excipients versus Nitricil alone. Figure 8 shows the NO gel stability over total time decreasing as a function of gel components. Figure 9 shows the antimicrobial time-death of gels showing Nitricil vs. formulated by hydrophobic gel in equivalent concentrations of silica prolongation release versus P. aeruginosa. Figure 10 shows the death-time effectiveness of the hydrophobic gel vs. hydrophilic against P. aeruginosa. Figure 11 shows the effectiveness of the dosage and time-death against P. acnes. Figure 12 shows the dosage and time-to-death efficacy against T. rubrum.

权利要求:
Claims (15)
[1]
1. Topical composition, characterized by the fact that it comprises nitric oxide release polysiloxane macromolecules, in which the nitric oxide release polysiloxane macromolecules are polysiloxane macromolecules functionalized by diazeniodiolate and a hydrophobic non-aqueous gel base, in which at least. minus 70% NO of nitric oxide-releasing polysiloxane macromolecules remain in the topical composition two days after the initial formulation when the topical composition is stored at room temperature.
[2]
2. Topical composition according to claim 1, characterized by the fact that the concentration of polysiloxane macromolecules functionalized with nitrogen dioxide and nitric oxide are in a range of 0.1% to 20% by weight of the topical composition.
[3]
Topical composition according to claim 1 or 2, characterized in that the hydrophobic non-aqueous gel base comprises a silicone gel.
[4]
Topical composition according to claim 1 or 2, characterized in that the hydrophobic non-aqueous gel base comprises petrolatum.
[5]
Topical composition according to claim 1 or 2, characterized in that the hydrophobic non-aqueous gel base comprises mineral oil.
[6]
6. Topical composition according to claim 5, characterized in that the mineral oil is present in the topical composition in a concentration in the range of 10% to 90% by weight of the topical composition.
[7]
7. Topical composition according to any of the
Petition 870200037495, of 03/20/2020, p. 63/73
2/4 claims 1 to 6, characterized by the fact that the hydrophobic non-aqueous gel base further comprises gel excipients and nitric oxide-releasing polysiloxane macromolecules, and the gel excipients have an octanol / water division coefficient in one range from 0.1 to 7, and / or where the nitric oxide-releasing polysiloxane macromolecules have a hydrodynamic radius in the range of 1000 nm to 10 microns or in the range of 1 nm to 100 nm.
[8]
Topical composition according to any one of claims 1 to 7, characterized in that the storage of nitric oxide per gram is in a range of 0.1 pmol NO / g to 100 nmol / g of the topical composition, or in a range of 1 nmol NO / g to 10 pmol / g of the topical composition, or in a range of 10 pmol NO / g to 1 mmol / g of the topical composition.
[9]
9. Topical composition, characterized by the fact that it comprises nitric oxide release polysiloxane macromolecules, in which the nitric oxide release polysiloxane macromolecules are polysiloxane macromolecules functionalized by diazeniodiolate and a hydrophilic gel base, in which at least 70 % NO of nitric oxide-releasing polysiloxane macromolecules remain in the topical composition two days after the initial formulation when the topical composition is stored at room temperature.
[10]
Topical composition according to claim 9, characterized by the fact that the concentration of the polysiloxane macromolecules that release nitrous oxide is in a range of 0.1% to 20% by weight of the percentage of the topical composition.
Petition 870200037495, of 03/20/2020, p. 64/73
3/4
[11]
Topical composition according to claim 9 or 10, characterized in that it also comprises hydroxypropylcellulose in a concentration in the range of 0.75% to 2.5% by weight of the topical composition, and in which the alcohol comprises isopropyl alcohol at a concentration in the range of 60% to 90% by weight of the topical composition.
[12]
Topical composition according to any one of claims 9 to 11, characterized in that the hydrophilic gel base further comprises gel excipients and polysiloxane macromolecules that release nitric oxide, and the gel excipients have a coefficient of division of octanol / water in a range of -2 to 0, and / or in which nitric oxide-releasing polysiloxane macromolecules have a hydrodynamic radius in the range of 1000 nm to 10 microns, or in the range of 1 nm to 100 nm.
[13]
Topical composition according to any one of claims 9 to 12, characterized in that the storage of nitric oxide per gram is in a range of 0.1 pmol NO / g to 100 nmol / g of the topical composition, or in a range of 1 nmol NO / g to 10 pmol / g of the topical composition, or in a range of 10 pmol NO / g to 1 mmol / g of the topical composition.
[14]
Topical composition according to any one of claims 1 to 13, characterized in that it still comprises a retinoid, antimicrobial agent, benzoyl peroxide or a corticosteroid.
[15]
15. Use of the topical composition as defined in any of claims 1 to 14, characterized by the fact that it is in the preparation of a medicament for the treatment of a wound, a burn, a disease of
Petition 870200037495, of 03/20/2020, p. 65/73
4/4 skin or acne.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US10376538B2|2019-08-13|Topical gels and methods of using the same

---

US20210322555A1|2021-10-21|Nitric oxide releasing pharmaceutical compositions

---

US20200061089A1|2020-02-27|Topical compositions

---

US10828323B2|2020-11-10|Topical compositions and methods of using the same

---

CN105813617B|2021-05-28|Topical compositions and methods of using the same

---

CN110035777A|2019-07-19|Preparation

---

US10912743B2|2021-02-09|Compositions for treating inflammation and methods of treating the same

---

CN102159191B|2014-04-02|Medicinal fusidic acid cream made using sodium fusidate and incorporating biopolymer and process for makeing same

---

CA3062005C|2022-02-15|Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof

同族专利:

---

公开号 | 公开日

---

WO2011022652A1|2011-02-24|

---

CN102711729A|2012-10-03|

---

CA3062005A1|2011-02-24|

---

US9526738B2|2016-12-27|

---

US20170312307A1|2017-11-02|

---

CA2771308A1|2011-02-24|

---

US9737561B2|2017-08-22|

---

EP2467127A1|2012-06-27|

---

US10376538B2|2019-08-13|

---

BR112012003792A2|2016-04-19|

---

US20170056437A1|2017-03-02|

---

US20120134951A1|2012-05-31|

---

CA2771308C|2020-01-21|

---

CN102711729B|2015-04-01|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4396615A|1981-06-24|1983-08-02|Duke University|Method of treating androgen-related disorders|

---

US4737550A|1983-01-07|1988-04-12|The Dow Chemical Company|Bridged dense star polymers|

---

US4507466A|1983-01-07|1985-03-26|The Dow Chemical Corporation|Dense star polymers having core, core branches, terminal groups|

---

US4631337A|1983-01-07|1986-12-23|The Dow Chemical Company|Hydrolytically-stable dense star polyamine|

---

US4568737A|1983-01-07|1986-02-04|The Dow Chemical Company|Dense star polymers and dendrimers|

---

US4558120A|1983-01-07|1985-12-10|The Dow Chemical Company|Dense star polymer|

---

US4587329A|1984-08-17|1986-05-06|The Dow Chemical Company|Dense star polymers having two dimensional molecular diameter|

---

US4600001A|1984-08-15|1986-07-15|The Kendall Company|Combined wound dressing and delivery means composite|

---

US4871779A|1985-12-23|1989-10-03|The Dow Chemical Company|Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities|

---

US4694064A|1986-02-28|1987-09-15|The Dow Chemical Company|Rod-shaped dendrimer|

---

US4713975A|1986-05-30|1987-12-22|The Dow Chemical Company|Dense star polymers for calibrating/characterizing sub-micron apertures|

---

US4857599A|1988-02-08|1989-08-15|The Dow Chemical Company|Modified dense star polymers|

---

US5061487A|1988-05-09|1991-10-29|Dow Corning Corporation|Antimicrobial superabsorbent compositions and methods|

---

US5045322A|1988-05-09|1991-09-03|Dow Corning Corporation|Antimicrobial superabsorbent sanitary napkin|

---

US4985023A|1988-05-09|1991-01-15|Dow Corning Corporation|Antimicrobial superabsorbent articles|

---

US4990338A|1988-05-09|1991-02-05|Dow Corning Corporation|Antimicrobial superabsorbent compositions and methods|

---

US5079004A|1990-08-06|1992-01-07|Dow Corning Corporation|Antimicrobial superabsorbent compositions and method|

---

US5035892A|1988-05-09|1991-07-30|Dow Corning Corporation|Antimicrobial superabsorbent compositions and methods|

---

US5380758A|1991-03-29|1995-01-10|Brigham And Women's Hospital|S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof|

---

EP0676964B1|1991-11-14|2001-01-24|Brigham And Women's Hospital|Nitrosylation of enzyme sh groups as a therapeutic modality|

---

US6291424B1|1991-11-14|2001-09-18|Brigham And Women's Hospital|Nitrosated and nitrosylated heme proteins|

---

GB9125712D0|1991-12-03|1992-01-29|Smithkline Beecham Plc|Skin care composition|

---

SE9200564L|1992-02-26|1993-03-15|Perstorp Ab|DENDRITIC MACROMOLECYLE OF POLYESTER TYPE, PROCEDURES FOR PRODUCING THEREOF AND USING THEREOF|

---

US5814666A|1992-04-13|1998-09-29|The United States As Represented By The Department Of Health And Human Services|Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents|

---

US5650447A|1992-08-24|1997-07-22|The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services|Nitric oxide-releasing polymers to treat restenosis and related disorders|

---

US6200558B1|1993-09-14|2001-03-13|The United States Of America As Represented By The Department Of Health And Human Services|Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same|

---

US5691423A|1992-08-24|1997-11-25|The United States Of America As Represented By The Department Of Health And Human Services|Polysaccharide-bound nitric oxide-nucleophile adducts|

---

US5632981A|1992-08-24|1997-05-27|The United States Of America As Represented By The Department Of Health And Human Services|Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same|

---

US5910316A|1992-08-24|1999-06-08|The United States Of America, As Represented By The Department Of Health And Human Services|Use of nitric oxide-releasing agents to treat impotency|

---

US5525357A|1992-08-24|1996-06-11|The United States Of America As Represented By The Department Of Health And Human Services|Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same|

---

US5405919A|1992-08-24|1995-04-11|The United States Of America As Represented By The Secretary Of Health And Human Services|Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders|

---

DE69637676D1|1995-11-09|2008-10-23|Univ R|Use of locally administered lysines to IMPROVE VASCULAR FUNCTION|

---

US5891459A|1993-06-11|1999-04-06|The Board Of Trustees Of The Leland Stanford Junior University|Enhancement of vascular function by modulation of endogenous nitric oxide production or activity|

---

US5852058A|1993-06-11|1998-12-22|The Board Of Trustees Of The Leland Stanford Junior University|Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury|

---

US5428070A|1993-06-11|1995-06-27|The Board Of Trustees Of The Leland Stanford Junior University|Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity|

---

US5861168A|1993-06-11|1999-01-19|The Board Of Trustees Of The Leland Stanford Junior University|Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury|

---

US6087479A|1993-09-17|2000-07-11|Nitromed, Inc.|Localized use of nitric oxide-adducts to prevent internal tissue damage|

---

US6255277B1|1993-09-17|2001-07-03|Brigham And Women's Hospital|Localized use of nitric oxide-adducts to prevent internal tissue damage|

---

EP0724436B1|1993-09-17|2004-01-07|Brigham And Women's Hospital|Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces|

---

US5840759A|1993-10-08|1998-11-24|The United States Of America As Represented By The Department Of Health And Human Services|Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents|

---

AU685178B2|1993-10-08|1998-01-15|United States Of America, Represented By The Secretary, Department Of Health And Human Services, The|Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers|

---

AT192922T|1993-11-02|2000-06-15|Us Health|USE OF NITROGEN OXIDE RELEASING COMPOUNDS FOR PRODUCING A MEDICINAL PRODUCT TO PROTECT AGAINST ISCHEMIC REPERFUSION DAMAGE|

---

US5599984A|1994-01-21|1997-02-04|The Picower Institute For Medical Research|Guanylhydrazones and their use to treat inflammatory conditions|

---

US6008255A|1994-01-21|1999-12-28|The Picower Institute For Medical Research|Guanylhydrazones and their use to treat inflammatory conditions|

---

US6709681B2|1995-02-17|2004-03-23|Aberdeen University|Acidified nitrite as an antimicrobial agent|

---

CZ286286B6|1994-02-21|2000-03-15|Aberdeen University|Antimicrobial preparation and application thereof|

---

US5935924A|1994-04-15|1999-08-10|Genentech, Inc.|Treatment of congestive heart failure|

---

CN1107499C|1994-05-27|2003-05-07|塞勒吉医药公司|Nitric oxide donor composition and method for treatment of anal disorders|

---

US5504117A|1994-05-27|1996-04-02|Neptune Pharmaceutical Corporation|Pharmacologic preparation for the treatment of anal disorders|

---

US6190704B1|1994-09-23|2001-02-20|New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery|Regulation of wound healing by nitric oxide|

---

US6747062B2|1994-09-26|2004-06-08|New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery|Regulation of wound healing by nitric oxide|

---

US5519020A|1994-10-28|1996-05-21|The University Of Akron|Polymeric wound healing accelerators|

---

US5629322A|1994-11-15|1997-05-13|Merck & Co., Inc.|Cyclic amidine analogs as inhibitors of nitric oxide synthase|

---

US5700830A|1994-11-22|1997-12-23|The United States Of America As Represented By The Department Of Health And Human Services|Use of nitric oxide-releasing agents for reducing metastasis risk|

---

US5999843A|1995-01-03|1999-12-07|Omnicorder Technologies, Inc.|Detection of cancerous lesions by their effect on the spatial homogeneity of skin temperature|

---

US5810010A|1995-01-03|1998-09-22|Anbar; Michael|Detection of cancerous lesions by their effect on the periodic modulation of perfusion in the surrounding tissues|

---

US5961466A|1995-01-03|1999-10-05|Omnicorder Technologies, Inc.|Method of detection of cancerous lesions by their effect on the spatial distribution of modulation of temperature and homogeneity of tissue|

---

US6035225A|1995-01-03|2000-03-07|Omnicorder Technologies|Detection of cancerous lesions by measuring nitric oxide concentrations in tissue|

---

DE69630514D1|1995-01-05|2003-12-04|Univ Michigan|SURFACE-MODIFIED NANOPARTICLES AND METHOD FOR THEIR PRODUCTION AND USE|

---

US5726156A|1995-03-06|1998-03-10|Trega Biosciences, Inc.|Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels|

---

US5786332A|1995-03-06|1998-07-28|Trega Biosciences, Inc.|Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels|

---

US5665077A|1995-04-24|1997-09-09|Nitrosci Pharmaceuticals Llc|Nitric oxide-releasing nitroso compositions and methods and intravascular devices for using them to prevent restenosis|

---

US5623981A|1995-08-17|1997-04-29|Service Station Products Company|Safety barrier for rim holding tire changers|

---

US6043358A|1995-11-01|2000-03-28|Merck & Co., Inc.|Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases|

---

US5821261A|1995-12-08|1998-10-13|Merck & Co., Inc.|Substituted saturated aza heterocycles as inhibitors of nitric oxide synthase|

---

US20050065161A1|1996-02-02|2005-03-24|Nitromed, Inc.|Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses|

---

US6294517B1|1996-02-02|2001-09-25|Nitromed, Inc.|Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use|

---

US5994294A|1996-02-02|1999-11-30|Nitromed, Inc.|Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses|

---

US20020143007A1|1996-02-02|2002-10-03|Garvey David S.|Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use|

---

US6323211B1|1996-02-02|2001-11-27|Nitromed, Inc.|Compositions and methods for treating sexual dysfunctions|

---

US5932538A|1996-02-02|1999-08-03|Nitromed, Inc.|Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses|

---

US6469065B1|1996-02-02|2002-10-22|Nitromed, Inc.|Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use|

---

US20020061879A1|1996-02-02|2002-05-23|Garvey David S.|Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses|

---

IT1282686B1|1996-02-26|1998-03-31|Nicox Sa|COMPOUNDS ABLE TO REDUCE DRUG TOXICITY|

---

CA2248558A1|1996-03-15|1997-09-18|Yale University|Methods and means of detecting nitric oxide synthase|

---

US6143037A|1996-06-12|2000-11-07|The Regents Of The University Of Michigan|Compositions and methods for coating medical devices|

---

US5965553A|1996-06-20|1999-10-12|Pfizer Inc.|Squalene synthetase inhibitors|

---

US6232434B1|1996-08-02|2001-05-15|Duke University Medical Center|Polymers for delivering nitric oxide in vivo|

---

US5770645A|1996-08-02|1998-06-23|Duke University Medical Center|Polymers for delivering nitric oxide in vivo|

---

US20030093143A1|1999-03-01|2003-05-15|Yiju Zhao|Medical device having surface depressions containing nitric oxide releasing compound|

---

US5797887A|1996-08-27|1998-08-25|Novovasc Llc|Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation|

---

EP0946160A4|1996-08-27|2007-05-09|Univ Akron|Lipophilic polyamine esters for the site specific delivery of nitric oxide in pharmaceutical use|

---

US6610660B1|1996-09-27|2003-08-26|The United States Of America As Represented By The Department Of Health And Human Services|O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[ pyrrolidin-1-yl] diazen-1-ium-1,2-diolates|

---

GB9622997D0|1996-11-05|1997-01-08|Univ St Andrews|Nitric oxide donor drugs|

---

US5958427A|1996-11-08|1999-09-28|Salzman; Andrew L.|Nitric oxide donor compounds and pharmaceutical compositions for pulmonary hypertension and other indications|

---

US6372796B1|1996-11-13|2002-04-16|Cold Spring Harbor Laboratory|Therapeutic uses for nitric oxide inhibitors|

---

US5891472A|1996-11-19|1999-04-06|Meri Charmyne Russell|Treatment of equine laminitis|

---

AT448782T|1996-12-31|2009-12-15|Antioxidant Pharmaceuticals Co|PHARMACEUTICAL GLUTATHION PREPARATIONS AND METHODS OF ADMINISTRATION|

---

US6896899B2|1996-12-31|2005-05-24|Antioxidant Pharmaceuticals Corp.|Pharmaceutical preparations of glutathione and methods of administration thereof|

---

BR9806767A|1997-01-17|2000-05-16|Cascade Eng Inc|Panel plate for a motor vehicle.|

---

AU6139798A|1997-02-04|1998-08-25|General Hospital Corporation, The|A novel method for treating epidermal or dermal conditions|

---

US6034752A|1997-03-22|2000-03-07|Kent Displays Incorporated|Display device reflecting visible and infrared radiation|

---

US6492405B2|1999-12-30|2002-12-10|Yissum Research Development Company Of The Hebrew University Of Jerusalem|Nitric oxide donors and pharmaceutical compositions containing them|

---

IL120531A|1997-03-26|2006-12-31|Yissum Res Dev Co|Nitric oxide donors and pharmaceutical compositions containing them|

---

US5968528A|1997-05-23|1999-10-19|The Procter & Gamble Company|Skin care compositions|

---

US6171232B1|1997-06-26|2001-01-09|Cordis Corporation|Method for targeting in vivo nitric oxide release|

---

EP1000023B1|1997-07-03|2011-02-23|THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES|Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same|

---

US6796966B2|1997-10-15|2004-09-28|Jeffrey E. Thomas|Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal|

---

WO1999018949A1|1997-10-15|1999-04-22|Thomas Jefferson University|Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal|

---

US5994444A|1997-10-16|1999-11-30|Medtronic, Inc.|Polymeric material that releases nitric oxide|

---

US20020013304A1|1997-10-28|2002-01-31|Wilson Leland F.|As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness|

---

CA2219867A1|1997-10-31|1999-04-30|Jiangping Wu|The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock|

---

JP4139860B2|1997-11-10|2008-08-27|ストラカンインターナショナルリミティッド|Penetration enhancement and stimulation reduction system|

---

US6180082B1|1997-11-24|2001-01-30|Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College|Method to enhance tissue accumulation of radiolabeled compounds|

---

AT277038T|1997-12-23|2004-10-15|Amersham Health As|NITROGEN OXIDE RELEASING CHELATIVERS AND THEIR THERAPEUTIC USE|

---

GB9801398D0|1998-01-22|1998-03-18|Anggard Erik E|Chemical compounds|

---

IT1298338B1|1998-03-05|1999-12-20|Nicox Sa|PHARMACEUTICAL COMPOSITIONS FOR THE ULCER|

---

US6151522A|1998-03-16|2000-11-21|The Research Foundation Of Cuny|Method and system for examining biological materials using low power CW excitation raman spectroscopy|

---

US6560478B1|1998-03-16|2003-05-06|The Research Foundation Of City University Of New York|Method and system for examining biological materials using low power CW excitation Raman spectroscopy|

---

US5962520A|1998-04-02|1999-10-05|The University Of Akron|Hydrolytically unstable, biocompatible polymer|

---

US6103266A|1998-04-22|2000-08-15|Tapolsky; Gilles H.|Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues|

---

US6103275A|1998-06-10|2000-08-15|Nitric Oxide Solutions|Systems and methods for topical treatment with nitric oxide|

---

US6207855B1|1998-06-23|2001-03-27|Duke University Medical Center|Stable no-delivering compounds|

---

US20020068365A1|1998-07-28|2002-06-06|Eric H. Kuhrts|Controlled release nitric oxide producing agents|

---

US6379691B1|1998-09-29|2002-04-30|Medtronic/Ave, Inc.|Uses for medical devices having a lubricious, nitric oxide-releasing coating|

---

US20040043068A1|1998-09-29|2004-03-04|Eugene Tedeschi|Uses for medical devices having a lubricious, nitric oxide-releasing coating|

---

US6299980B1|1998-09-29|2001-10-09|Medtronic Ave, Inc.|One step lubricious coating|

---

DE19852681A1|1998-11-16|2000-05-18|Basf Ag|Carbamate solutions|

---

CA2254645A1|1998-11-23|2000-05-23|Pulmonox Medical Corporation|Method and apparatus for treatment of respiratory infections by nitric oxide inhalation|

---

US20070275100A1|1998-11-23|2007-11-29|Miller Christopher C|Use of gaseous nitric oxide as an anti-cancer agent|

---

US20070086954A1|1998-11-23|2007-04-19|Miller Christopher C|Method and apparatus for treatment of respiratory infections by nitric oxide inhalation|

---

US6207664B1|1998-11-25|2001-03-27|Pfizer Inc.|Squalene synthetase inhibitor agents|

---

US6261594B1|1998-11-25|2001-07-17|The University Of Akron|Chitosan-based nitric oxide donor compositions|

---

US7179475B1|1998-12-04|2007-02-20|Johnson & Johnson Consumer Companies, Inc.|Anhydrous topical skin preparations|

---

US6238683B1|1998-12-04|2001-05-29|Johnson & Johnson Consumer Companies, Inc.|Anhydrous topical skin preparations|

---

US20050142218A1|2000-03-09|2005-06-30|Queen Mary & Westfield College|Pharmaceutical composition containing nitrate source and an acidifying agent for treating skin ischaemia|

---

GB9905425D0|1999-03-09|1999-05-05|Queen Mary & Westfield College|Pharmaceutical composition|

---

US6312663B1|1999-03-19|2001-11-06|Joseph V. Boykin, Jr.|Prediction of diabetes impaired wound healing by urinary nitrate assay|

---

US6562785B1|1999-03-23|2003-05-13|Howard M. Shapiro|Method for overcoming bacterial antibiotic resistance|

---

US7655423B2|1999-06-14|2010-02-02|Henry Ford Health System|Nitric oxide donors for inducing neurogenesis|

---

ES2313895T3|1999-06-14|2009-03-16|Henry Ford Health System|DONATORS OF NITRIC OXIDE TO INDUCE NEUROGENESIS.|

---

US7135498B1|1999-06-14|2006-11-14|Henry Ford Health System|Nitric oxide donors for inducing neurogenesis|

---

US20010012851A1|1999-07-29|2001-08-09|Kristin M. Lundy|Nitric oxide releasing oxindole prodrugs for anagesic, anti-inflammatory and disease-modifying use|

---

US20020049157A1|1999-08-25|2002-04-25|Jiangping Wu|Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock|

---

US7279176B1|1999-09-02|2007-10-09|Rice University|Nitric oxide-producing hydrogel materials|

---

JP4841066B2|2000-09-01|2011-12-21|ライスユニバーシティ|Nitric oxide-forming hydrogel materials|

---

IL143305D0|1999-09-02|2002-04-21|Rice University|Nitric oxide-producing hydrogel materials|

---

US7052711B2|1999-09-02|2006-05-30|Rice University|Nitric oxide-producing hydrogel materials|

---

US6479058B1|1999-09-02|2002-11-12|Mccadden Michael E.|Composition for the topical treatment of poison ivy and other forms of contact dermatitis|

---

US6790910B1|1999-09-09|2004-09-14|Creavis Gesellschaft Fuer Technologie Und Innovation Mbh|Antimicrobial additives|

---

DE19945484A1|1999-09-22|2001-04-05|Kolb Bachofen Victoria|NO-releasing topically applicable composition|

---

US6737447B1|1999-10-08|2004-05-18|The University Of Akron|Nitric oxide-modified linear poly fibers and uses thereof|

---

CA2394997A1|1999-12-20|2001-06-28|Sa Majeste La Reine Du Chef Du Canada Agriculture Et Agroalimentaire Can Ada|Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections|

---

WO2001053537A2|2000-01-24|2001-07-26|Dzgenes, Llc|Nitric oxide synthase gene diagnostic polymorphisms|

---

US6758214B2|2000-01-28|2004-07-06|Cyterra Corporation|Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment|

---

US6699846B2|2000-03-17|2004-03-02|Corixa Corporation|Mono- and disaccharides for the treatment of nitric oxide related disorders|

---

AU4757901A|2000-03-20|2001-10-03|Novovascular Inc|Matrices containing nitric oxide donors and reducing agents and their use|

---

US20010038832A1|2000-04-11|2001-11-08|Benjamin Bonavida|Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity|

---

EP1278547B1|2000-04-26|2004-11-03|Cellegy Pharmaceuticals, Inc|Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype|

---

US20050142217A1|2000-04-26|2005-06-30|Adams Michael A.|Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype|

---

US7678391B2|2000-04-26|2010-03-16|Queen's University At Kingston|Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype|

---

US20010053772A1|2000-04-28|2001-12-20|Benjamin Bonavida|Aza analogues of alkyl lysophospholipids exert immunomodulatory effects|

---

US6270779B1|2000-05-10|2001-08-07|United States Of America|Nitric oxide-releasing metallic medical devices|

---

AU6472901A|2000-05-22|2001-12-03|Nitromed Inc|Thromboxane inhibitors, compositions and methods of use related applications|

---

US6623728B2|2000-06-30|2003-09-23|Unilever Home & Personal Care Usa Division Of Conopco, Inc.|Cosmetic skin care compositions and containing gum mastic|

---

US6475500B2|2000-07-10|2002-11-05|The Procter & Gamble Company|Anhydrous cosmetic compositions|

---

US6538033B2|2000-08-29|2003-03-25|Huntington Medical Research Institutes|Nitric oxide donor compounds|

---

GB0021317D0|2000-08-30|2000-10-18|Queen Mary & Westfield College|Transdermal pharmaceutical delivery composition|

---

GB0022084D0|2000-09-08|2000-10-25|Univ Aberdeen|Treatment of multiply antibiotic-resistant organisms|

---

US6410622B1|2000-09-11|2002-06-25|Gregory W. Endres|Method of preventing fouling organisms in marine environments and polymer-bound nitric oxide/nitric oxide-releasing compositions usable therefor|

---

JP4194364B2|2000-10-16|2008-12-10|デューク・ユニバーシティ|Therapeutic use of aerosolized S-nitrosoglutathione in cystic fibrosis|

---

CA2425196A1|2000-10-17|2002-04-25|Board Of Regents, The University Of Texas System|A method to incorporate n- retinamide in liposomes|

---

US7049308B2|2000-10-26|2006-05-23|Duke University|C-nitroso compounds and use thereof|

---

US6359182B1|2000-10-26|2002-03-19|Duke University|C-nitroso compounds and use thereof|

---

KR100383149B1|2000-12-12|2003-05-12|한국생명공학연구원|A novel use of diterpene compounds as therapeutic agents of inflammation, immune disease and cancer|

---

DE10063937A1|2000-12-20|2002-07-18|Bayer Ag|Process for the preparation of trimethylol compounds and formic acid|

---

US6780849B2|2000-12-21|2004-08-24|Scimed Life Systems, Inc.|Lipid-based nitric oxide donors|

---

US7329412B2|2000-12-22|2008-02-12|The Trustees Of Columbia University In The City Of New York|Antimicrobial medical devices containing chlorhexidine free base and salt|

---

US6432077B1|2000-12-26|2002-08-13|Sensormedics Corporation|Device and method for treatment of surface infections with nitric oxide|

---

US7122018B2|2000-12-26|2006-10-17|Sensormedics Corporation|Device and method for treatment of wounds with nitric oxide|

---

JP2004516369A|2000-12-27|2004-06-03|ワールド・プロパティーズ・インコーポレイテッド|Polyurethane foam and method for producing the same|

---

ES2312547T3|2001-01-16|2009-03-01|The Regents Of The University Of Michigan|IN SITU BIOCATALITICS AND BIOMIMETIC GENERATION OF NITRIC OXIDE IN SUBSTRATE / BLOOD INTERFASES.|

---

US7128904B2|2001-01-16|2006-10-31|The Regents Of The University Of Michigan|Material containing metal ion ligand complex producing nitric oxide in contact with blood|

---

US7335383B2|2001-01-16|2008-02-26|The Regents Of The University Of Michigan|Generation of nitric oxide in vivo from nitrite, nitrate or nitrosothiols endogenous in blood|

---

US6706274B2|2001-01-18|2004-03-16|Scimed Life Systems, Inc.|Differential delivery of nitric oxide|

---

ITMI20010426A1|2001-03-01|2002-09-02|Consiglio Nazionale Ricerche|NITROGEN OXIDE DONORS BASED ON METAL CENTERS|

---

US7012098B2|2001-03-23|2006-03-14|Pharmacia Corporation|Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers|

---

US20020138051A1|2001-03-26|2002-09-26|Hole Douglas R.|System and method for the prevention and treatment of animal wound infections using nitric oxide|

---

US6710037B2|2001-05-01|2004-03-23|Schering Corporation|Method of treating androgen-dependent disorders|

---

WO2002096387A1|2001-05-25|2002-12-05|Medtronic, Inc.|Implantable medical device with controllable gaseous agent release system|

---

AU2002304816A1|2001-06-07|2002-12-16|Aarhus Universitet|Modulation of steroid hormone uptake|

---

ES2180446B1|2001-07-02|2004-01-16|Esteve Labor Dr|EMPLOYMENT OF 2,5-DIHYDROXIBENCENOSULPHONIC ACID DERIVATIVES IN THE PREPARATION OF A MEDICINAL PRODUCT TO POWER THE EFFECT OF OTHER PHARMACOS IN THE TREATMENT OF ERECTILE DYSFUNCTION.|

---

WO2003006427A1|2001-07-12|2003-01-23|Johns Hopkins University|Compounds that release nitric oxide at controlled rates upon photolysis|

---

GB0119011D0|2001-08-03|2001-09-26|Univ Aberdeen|Treatment of nail infections|

---

WO2003015605A2|2001-08-20|2003-02-27|University Of Virginia Patent Foundation|Use of s-nitrosothiol signaling to treat disordered control of breathing|

---

US6841166B1|2001-08-21|2005-01-11|The Regents Of The University Of Michigan|Nitric oxide-releasing polymers incorporating diazeniumdiolated silane derivatives|

---

US7135189B2|2001-08-23|2006-11-14|Boston Scientific Scimed, Inc.|Compositions and techniques for localized therapy|

---

WO2003020211A2|2001-09-05|2003-03-13|Cyterra Corporation|Nitric oxide generation|

---

US6673338B1|2001-09-10|2004-01-06|The United States Of America As Represented By The Department Of Health And Human Services|Nitric oxide-releasing imidate and thioimidate diazeniumdiolates, compositions, uses thereof and method of making same|

---

WO2003026717A1|2001-09-26|2003-04-03|The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services|Nitric oxide-releasing coated medical devices and method of preparing same|

---

EP1300083A1|2001-10-04|2003-04-09|Societe Des Produits Nestle S.A.|Milk-based snack|

---

US6703046B2|2001-10-04|2004-03-09|Medtronic Ave Inc.|Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use|

---

GB0125222D0|2001-10-19|2001-12-12|Barts & London Nhs Trust|Composition for the treatment of microbial infections|

---

US20040110691A1|2001-11-13|2004-06-10|Stamler Jonathan S.|Thiol reactive agents as a therapeutic modality|

---

US6472390B1|2001-11-13|2002-10-29|Duke University|Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure|

---

US6627602B2|2001-11-13|2003-09-30|Duke University|Preventing desensitization of receptors|

---

CN1612804A|2001-12-03|2005-05-04|C·R·巴德公司|Microbe-resistant medical device, microbe-resistant polymeric coating and methods for producing same|

---

US7176237B2|2002-01-15|2007-02-13|The Trustees Of Dartmouth College|Tricyclic-bis-enone derivatives and methods of use thereof|

---

US20040254419A1|2003-04-08|2004-12-16|Xingwu Wang|Therapeutic assembly|

---

US20050079132A1|2003-04-08|2005-04-14|Xingwu Wang|Medical device with low magnetic susceptibility|

---

US6474508B1|2002-01-24|2002-11-05|Saint-Gobain Calmar Inc.|Unit dose tube and cap assembly|

---

US7250442B2|2002-03-15|2007-07-31|Eli Lilly And Company|Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators|

---

US20030219854A1|2002-03-21|2003-11-27|Micrologix Biotech Inc.|Methods for producing modified anti-infective peptides|

---

AU2003230715A1|2002-03-21|2003-10-08|The University Of Utah Research Foundation|In vivo use of glutathionone s-transferase activated nitric oxide donors|

---

US20040076582A1|2002-08-30|2004-04-22|Dimatteo Kristian|Agent delivery particle|

---

JP4969768B2|2002-04-04|2012-07-04|ザユニバーシティオブアクロン|Nonwoven fiber assembly|

---

AU2003223491A1|2002-04-05|2003-10-27|Nitromed, Inc.|Nitric oxide donors, compositions and methods of use|

---

WO2003092763A1|2002-05-03|2003-11-13|Duke University|Carbon nanotubules for storage of nitric oxide|

---

AU2003234510A1|2002-05-07|2003-11-11|The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt|Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same|

---

JP2006515859A|2002-05-13|2006-06-08|トラスティーズオブダートマスカレッジ|Inhibitors and uses thereof|

---

US7070798B1|2002-06-21|2006-07-04|Advanced Cardiovascular Systems, Inc.|Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine|

---

JP2005533812A|2002-06-21|2005-11-10|ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション|Pharmaceutical use of nitric oxide, heme oxygenase-1 and heme degradation products|

---

US20040009238A1|2002-07-09|2004-01-15|Chris Miller|Exogenenous nitric oxide gas therapy in wound healing|

---

US6949530B2|2002-07-18|2005-09-27|The United States Of America As Represented By The Department Of Health And Human Services|Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same|

---

AU2003252033A1|2002-07-19|2004-02-09|University Of North Carolina At Chapel Hill|Surface-localized release of an anti-biofouling agent via micropatterning|

---

CA2493082A1|2002-07-26|2004-02-05|Merck Frosst Canada & Co./Merck Frosst Canada & Cie|Nitric oxide releasing prodrugs of diaryl-2--furanones as cyclooxygenase-2 inhibitors|

---

EP1545798A4|2002-08-02|2006-06-14|Us Gov Health & Human Serv|Cross-linked nitric oxide-releasing polyamine coated substrates, compositions comprising same and method of making same|

---

US20020182162A1|2002-08-07|2002-12-05|Mohsen Shahinpoor|Nitric oxide donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth|

---

US20050080021A1|2002-08-15|2005-04-14|Joseph Tucker|Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders|

---

US20040033480A1|2002-08-15|2004-02-19|Wong Norman C.W.|Use of resveratrol to regulate expression of apolipoprotein A1|

---

US20050080024A1|2002-08-15|2005-04-14|Joseph Tucker|Nitric oxide donating derivatives for the treatment of cardiovascular disorders|

---

US6951902B2|2002-08-16|2005-10-04|Michigan Biotechnology Institute|Two dimensional polymer that generates nitric oxide|

---

US7674482B2|2002-08-27|2010-03-09|Targeted Medical Pharma Inc.|Method and compositions for potentiating pharmaceuticals with amino acid based medical foods|

---

US20100210745A1|2002-09-09|2010-08-19|Reactive Surfaces, Ltd.|Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes|

---

US20030039697A1|2002-09-12|2003-02-27|Yi-Ju Zhao|Matrices containing nitric oxide donors and reducing agents and their use|

---

AU2003278039A1|2002-10-22|2004-05-13|Merck Frosst Canada And Co.|Nitric oxide releasing selective cyclooxygenase-2 inhibitors|

---

US9668972B2|2002-10-25|2017-06-06|Foamix Pharmaceuticals Ltd.|Nonsteroidal immunomodulating kit and composition and uses thereof|

---

IL152486D0|2002-10-25|2003-05-29|Meir Eini|Alcohol-free cosmetic and pharmaceutical foam carrier|

---

US20080206161A1|2002-10-25|2008-08-28|Dov Tamarkin|Quiescent foamable compositions, steroids, kits and uses thereof|

---

US20080031907A1|2002-10-25|2008-02-07|Foamix Ltd.|Cosmetic and pharmaceutical foam|

---

US20070292359A1|2002-10-25|2007-12-20|Foamix Ltd.|Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof|

---

CA2711703A1|2008-01-08|2009-07-16|Foamix Ltd.|Sensation modifying topical composition foam|

---

US9265725B2|2002-10-25|2016-02-23|Foamix Pharmaceuticals Ltd.|Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof|

---

US20080152596A1|2005-07-19|2008-06-26|Foamix Ltd.|Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof|

---

US20080138296A1|2002-10-25|2008-06-12|Foamix Ltd.|Foam prepared fromnanoemulsions and uses|

---

WO2008038140A2|2006-06-07|2008-04-03|Foamix Ltd.|Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof|

---

US20050271596A1|2002-10-25|2005-12-08|Foamix Ltd.|Vasoactive kit and composition and uses thereof|

---

US20080317679A1|2002-10-25|2008-12-25|Foamix Ltd.|Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses|

---

GB0224986D0|2002-10-28|2002-12-04|Smith & Nephew|Apparatus|

---

AU2005239984B2|2002-10-29|2010-06-03|Brigham Young University|Use of equol for treating skin diseases|

---

AU2003282883B2|2002-11-18|2008-12-04|Polaris Group|Methods for inhibiting viral replication in vivo|

---

AU2003293529A1|2002-12-16|2004-07-29|Nitromed, Inc.|Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use|

---

CA2511806A1|2003-01-22|2004-08-12|Eli Lilly And Company|Indole-derivative modulators of steroid hormone nuclear receptors|

---

WO2004064767A2|2003-01-23|2004-08-05|Kahn Nighat N|Nitric oxide inducing agents|

---

FR2850578B1|2003-02-03|2006-07-28|Oreal|USE OF N-ARYLMETHYLENE ETHYLENEDIAMINETRIACETATES, N-ARYLMETHYLENEIMINODIACETATES OR N, N'-DIARYLMETHYLENE ETHYLENEDIAMINEACETATES AS DONORS OF NO|

---

EP1601644B1|2003-03-05|2009-05-27|Merck Frosst Company|Nitric oxide releasing prodrugs of diaryl-2--furanones as cyclooxygenase-2 inhibitors|

---

AU2004237574A1|2003-03-13|2004-11-18|Nitromed, Inc.|Nitrosated and nitrosylated compounds, compositions and methods of use|

---

SE0300971D0|2003-04-03|2003-04-03|Aga Ab|Nitric oxide in the treatment of inflammation|

---

EP1491188A1|2003-06-25|2004-12-29|G2M Cancer Drugs AG|Topical use of valproic acid for the prevention or treatment of skin disorders|

---

US7972137B2|2003-06-30|2011-07-05|Rosen Gerald M|Anti-microbial dental formulations for the prevention and treatment of oral mucosal disease|

---

US7256921B2|2003-07-01|2007-08-14|Transitions Optical, Inc.|Polarizing, photochromic devices and methods of making the same|

---

CA2530811C|2003-07-03|2013-01-08|The University Court Of The University Of St Andrews|Zeolites for delivery of nitric oxide|

---

DE10330960B4|2003-07-08|2005-09-08|Stockhausen Gmbh|Active substance-doped absorbent polymer particles, composition comprising polycondensate matrix and absorbent polymer for release of a wound healing substance|

---

US7234079B2|2003-07-11|2007-06-19|Agency For Science, Technology & Research|Method and system for enabling recovery of data stored in a computer network; a method and a system for recovering data stored in a computer network|

---

US20050038473A1|2003-07-14|2005-02-17|Dov Tamarkin|Device and method for the treatment of pilosebaceous disorders|

---

US20050054714A1|2003-07-17|2005-03-10|Benito Munoz|Nitric oxide releasing drugs for Alzheimer's disease|

---

EP1648527A4|2003-07-25|2008-04-23|Univ Akron|Stabilization and ionic triggering of nitric oxide release|

---

US8795693B2|2003-08-04|2014-08-05|Foamix Ltd.|Compositions with modulating agents|

---

US8486374B2|2003-08-04|2013-07-16|Foamix Ltd.|Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses|

---

US20070292461A1|2003-08-04|2007-12-20|Foamix Ltd.|Oleaginous pharmaceutical and cosmetic foam|

---

US7704518B2|2003-08-04|2010-04-27|Foamix, Ltd.|Foamable vehicle and pharmaceutical compositions thereof|

---

US20080069779A1|2003-08-04|2008-03-20|Foamix Ltd.|Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof|

---

US20080292560A1|2007-01-12|2008-11-27|Dov Tamarkin|Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent|

---

US7364585B2|2003-08-11|2008-04-29|Boston Scientific Scimed, Inc.|Medical devices comprising drug-loaded capsules for localized drug delivery|

---

US7314857B2|2003-08-25|2008-01-01|Kane Biotech Inc.|Synergistic antimicrobial compositions and methods of inhibiting biofilm formation|

---

US20070238740A1|2003-08-28|2007-10-11|Nitromed, Inc.|Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use|

---

JP2007518697A|2003-09-26|2007-07-12|ニトロメッドインコーポレーティッド|Nitrosated glutamic acid compounds, compositions, and methods of use|

---

US20070148136A1|2003-09-26|2007-06-28|Whitlock David R|Methods of using ammonia oxidizing bacteria|

---

US7485324B2|2003-09-29|2009-02-03|Pulmonox Technologies Corporation|Use of exogenous gaseous nitric oxide in the treatment and disinfection of biofilms|

---

US20070154570A1|2004-09-29|2007-07-05|Miller Christopher C|Use of nitric oxide in the treatment and disinfection of biofilms|

---

US20050074506A1|2003-10-02|2005-04-07|Brainsgate Ltd.|Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders|

---

EP1677849A1|2003-10-14|2006-07-12|Cube Medical A/S|A balloon for use in angioplasty|

---

US20060286158A1|2003-10-17|2006-12-21|Calvert Murrell George A|Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents|

---

US20060286159A1|2003-10-17|2006-12-21|Calvert Murrell George A|Treatment of persistent active tendinopathy using transdermal glyceryl trinitrate providing durability of effect|

---

US20050171199A1|2003-10-17|2005-08-04|New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery|Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents|

---

US20070053966A1|2003-10-17|2007-03-08|Robert Ang|Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue|

---

US20070059351A1|2003-10-17|2007-03-15|Murrell George A C|Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods|

---

AU2004296174A1|2003-12-15|2005-06-23|Nitricare Hb|Device and method for administering therapeutic agents|

---

US8017074B2|2004-01-07|2011-09-13|Noxilizer, Inc.|Sterilization system and device|

---

WO2005067986A1|2004-01-07|2005-07-28|Noxilizer, Inc.|Sterilization system and device|

---

WO2005070006A2|2004-01-22|2005-08-04|Nitromed, Inc.|Nitrosated and/or nitrosylated compounds, compositions and methods of use|

---

AU2005207039A1|2004-01-22|2005-08-04|Reneker, Darrell|Polymer NO donor predrug nanofiber coating for medical devices and therapy|

---

US7622501B2|2004-01-27|2009-11-24|Merck Frosst Canada & Co.|Nitric oxide releasing prodrugs of diaryl-2--furanones as cyclooxygenase-2 inhibitors|

---

JP2007520484A|2004-01-27|2007-07-26|メルクフロストカンパニー|Diaryl-2- -furanone nitric oxide releasing prodrug as cyclooxygenase-2 inhibitor|

---

US20050165452A1|2004-01-28|2005-07-28|Medtronic, Inc.|Antithrombogenic medical device|

---

AU2005215970A1|2004-02-09|2005-09-09|Noxilizer, Inc.|Nitric oxide-releasing molecules|

---

US7569559B2|2004-02-09|2009-08-04|Noxilizer, Inc.|Nitric oxide-releasing molecules|

---

EP1718656A2|2004-02-10|2006-11-08|Purdue Research Foundation|Crowned dithiocarbamate metal complexes and methods for their use|

---

AU2005216192B2|2004-02-23|2010-11-04|Strategic Science & Technologies, Llc|Topical delivery of a nitric oxide donor to improve body and skin appearance|

---

CA2561141A1|2004-03-31|2005-11-17|Nitromed, Inc.|Methods for treating blood disorders with nitric oxide donor compounds|

---

EP1737429B1|2004-04-19|2013-07-17|Strategic Science & Technologies, LLC|Transdermal delivery of beneficial substances effected by a high ionic strength environment|

---

WO2005115440A2|2004-04-29|2005-12-08|Kahn Nighat N|Compositions and method for modulating insulin-activated nitric oxide synthase|

---

WO2005115417A2|2004-05-03|2005-12-08|Neosil, Inc.|Polycationic antimicrobial therapeutic|

---

WO2005112954A1|2004-05-14|2005-12-01|William Marsh Rice University|Nitric oxide releasing compositions and associated methods|

---

US8791073B2|2004-05-14|2014-07-29|William Marsh Rice University|Peptide-modified polyurethane compositions and associated methods|

---

US7582623B2|2004-05-20|2009-09-01|The Regents Of The University Of California|Photoactive metal nitrosyls for blood pressure regulation and cancer therapy|

---

WO2005120493A1|2004-06-10|2005-12-22|Tohoku University|Anticancer effect enhancer|

---

US20060008529A1|2004-07-12|2006-01-12|Meyerhoff Mark E|Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers|

---

US20060039950A1|2004-08-23|2006-02-23|Zhengrong Zhou|Multi-functional biocompatible coatings for intravascular devices|

---

US7968664B2|2004-09-27|2011-06-28|The United States Of America As Represented By The Department Of Health And Human Services|Nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers, and compositions, medical devices, and uses thereof|

---

US8067464B2|2004-10-04|2011-11-29|Nitromed, Inc.|Compositions and methods using apocynin compounds and nitric oxide donors|

---

FR2877004B1|2004-10-21|2007-03-09|Oreal|ESTERS AND SILANIC AMIDES OF 2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID AND THEIR COSMETIC USES.|

---

US8388677B2|2004-10-29|2013-03-05|Boston Scientific Scimed, Inc.|Anti-thrombogenic and anti-restenotic vascular medical devices|

---

AU2005306629A1|2004-11-15|2006-05-26|Nicox S.A.|Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use|

---

US20070166255A1|2004-11-22|2007-07-19|Gupta Shyam K|Treatment of Topical Discomforts Including Acne, Sunburn, Diaper Rash, Wound, Wrinkles and Dandruff/Hair Loss by Natural Lignans via Fatty Acid Desaturase Inhibition|

---

US20090214624A1|2004-11-29|2009-08-27|The University Of Akron|Topical nitric oxide donor devices and methods for their therapeutic use|

---

EP1681068A1|2004-12-16|2006-07-19|NOLabs AB|Anti-pathogen and anti-cancer filtering device and method comprising nitric oxide|

---

WO2006064056A2|2004-12-16|2006-06-22|Nolabs Ab|Anti-pathogen and anti-cancer filtering device and method comprising nitric oxide|

---

CA2592407A1|2004-12-24|2006-06-29|The University Of Queensland|Methods of treating pain|

---

NZ560386A|2005-01-31|2009-12-24|Mylan Lab Inc|Pharmaceutical composition comprising hydroxylated nebivolol|

---

EP1690557A1|2005-02-11|2006-08-16|NOLabs AB|Device for treatment of rectal disorders, and manufacturing process for the same|

---

EP1690558A1|2005-02-11|2006-08-16|NOLabs AB|Device for treatment of diabetic disorders|

---

WO2006084914A2|2005-02-11|2006-08-17|Nolabs Ab|Device for gastric treatment and manufacturing process for the same|

---

CA2594407C|2005-02-11|2014-06-10|Nolabs Ab|Device method, and use for treatment of neuropathy involving nitric oxide|

---

WO2006084913A2|2005-02-11|2006-08-17|Nolabs Ab|Device for treatment of rectal disorders, and manufacturing process for the same, involving nitric oxide|

---

WO2006084911A2|2005-02-11|2006-08-17|Nolabs Ab|Improved device for application of medicaments, manufacturing method therefor, and method of treatment|

---

EP1690554A1|2005-02-11|2006-08-16|NOLabs AB|Device for treatment of infections, including dermatophytosis and onychomycosis|

---

EP1700611A1|2005-02-11|2006-09-13|NOLabs AB|Device for treatment of disorders in the oral cavity, and manufacturing process for the same|

---

EP1690532A1|2005-02-11|2006-08-16|NOLabs AB|Device for gastric treatment and manufacturing process for the same|

---

DE602006002726D1|2005-02-11|2008-10-23|Nolabs Ab|DEVICE AND METHOD FOR THE TREATMENT OF DERMATOMYCOSES AND IN PARTICULAR ONYCHOMYCOSES|

---

CA2597422A1|2005-02-16|2007-08-02|Nitromed, Inc.|Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use|

---

AU2006216665A1|2005-02-24|2006-08-31|Nicox S.A.|Nitric oxide enhancing diuretic compounds, compositions and methods of use|

---

US8119840B2|2005-03-04|2012-02-21|The University Of Akron|Ethambutol based nitric oxide donors|

---

JP2008533031A|2005-03-09|2008-08-21|ニトロメッドインコーポレーティッド|Organic nitric oxide enhancing salts, compositions and methods of use of angiotensin II antagonists|

---

GB0505035D0|2005-03-11|2005-04-20|Insense Ltd|Improvements relating to skin dressings|

---

WO2006097348A1|2005-03-15|2006-09-21|L'oreal|Use of agents such as nonpolymeric nitric oxide donors for making the lips full again and/or colouring the lips|

---

EP1704879A1|2005-03-24|2006-09-27|NOLabs AB|Intravascular, interstitial or intraorgan medical device comprising a nitric oxide eluting polymer|

---

JP2008534037A|2005-03-24|2008-08-28|ノーラブズエービー|Intravascular, tissue or organ medical access device containing nitric oxide and method for producing the same|

---

EP1704876A1|2005-03-24|2006-09-27|NOLabs AB|Cosmetic treatment, device for performing said treatment and manufacturing method thereof|

---

WO2006100155A1|2005-03-24|2006-09-28|Nolabs Ab|Device for wound care, and manufacturing method thereof, involving the use of nitric oxide|

---

US9427605B2|2005-03-24|2016-08-30|Novan, Inc.|Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor|

---

EP1704877A1|2005-03-24|2006-09-27|NOLabs AB|A wound care device comprising a nitric oxide eluting polymer|

---

AU2006313443A1|2005-05-09|2007-05-18|Foamix Ltd.|Foamable vehicle and pharmaceutical compositions thereof|

---

FR2885527B1|2005-05-16|2007-06-29|Galderma Res & Dev|PHARMACEUTICAL COMPOSITION COMPRISING AN OLEAGINOUS OINTMENT AND VITAMIN D OR ITS DERIVATIVES IN THE SOLUBILIZED CONDITION|

---

EP1885375A4|2005-05-16|2010-12-01|Univ Alberta|Novel nsaids possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety|

---

WO2006122573A1|2005-05-17|2006-11-23|Syntach Ag|A device a kit for treatment of disorders in the heart rhythm regulation system|

---

WO2006127591A2|2005-05-23|2006-11-30|Nitromed, Inc.|Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use|

---

DK2351828T3|2005-05-24|2018-01-22|Univ Nanyang Tech|Methods and compositions for regulating biofilm development|

---

CA2606565C|2005-05-27|2016-05-10|The University Of North Carolina At Chapel Hill|Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications|

---

EP1728438A1|2005-06-01|2006-12-06|NOLabs AB|Feedstuff|

---

WO2006128742A2|2005-06-01|2006-12-07|Nolabs Ab|Treatment and pre-treatment device, and manufacturing method therefor, involving nitric oxide|

---

EP1731176A1|2005-06-01|2006-12-13|NOLabs AB|Pre-treatment device comprising nitric oxide|

---

WO2006128743A1|2005-06-01|2006-12-07|Nolabs Ab|Feedstuff|

---

CA2820200C|2005-06-09|2015-08-18|Judith Esther Anderson|Compositions and methods for enhancing nitric oxide delivery|

---

US20090118819A1|2005-06-30|2009-05-07|Mc3, Inc.|Nitric Oxide Coatings for Medical Devices|

---

WO2007005758A2|2005-06-30|2007-01-11|Mc3, Inc.|Methods , compositions and devices for promoting angiogenesis|

---

AU2006265707B2|2005-07-01|2012-06-14|Kane Biotech Inc.|Antimicrobial compositions for inhibiting growth and proliferation of a microbial biofilm on medical devices|

---

US20080139450A1|2005-07-01|2008-06-12|Srinivasa Madhyastha|Antimicrobial Compositions and Uses Thereof|

---

BRPI0503201B8|2005-07-28|2021-05-25|Sci Tech Produtos Medicos Ltda|stents coated with hydrophilic polymer blends, eluting nitric oxide and s-nitrosothiols|

---

US20090018091A1|2005-08-02|2009-01-15|Nitromed, Inc.|Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use|

---

EP1757278A1|2005-08-23|2007-02-28|NOLabs AB|Device, system, and method comprising microencapsulated liquid for release of nitric oxide from a polymer|

---

JP2009505727A|2005-08-25|2009-02-12|メドトロニックヴァスキュラーインコーポレイテッド|Nitric oxide releasing biodegradable polymers useful as medical devices and their coatings|

---

EP1919304B1|2005-08-26|2011-05-25|Nestec S.A.|Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis after an ischemic episode in the brain|

---

US20070048344A1|2005-08-31|2007-03-01|Ali Yahiaoui|Antimicrobial composition|

---

US20070053952A1|2005-09-07|2007-03-08|Medtronic Vascular, Inc.|Nitric oxide-releasing polymers derived from modified polymers|

---

US20090010989A1|2005-09-12|2009-01-08|N0Labs Ab|Coating For Implants and Implants With Improved Osteointegration, and Manufacturing Method|

---

EP1764119A1|2005-09-09|2007-03-21|NOLabs AB|Implants with improved osteointegration|

---

JP2009511515A|2005-10-11|2009-03-19|バイエル・コンシューマー・ケア・アクチェンゲゼルシャフト|A mixture of iron and copper salts masking the taste of metals|

---

US20070088345A1|2005-10-13|2007-04-19|Ust Inc.|Applications of HIFU and chemotherapy|

---

US7531164B2|2005-10-21|2009-05-12|Duke University|Preventing bacterial or viral infectivity and composition containing infection preventing additive|

---

WO2007053578A2|2005-10-31|2007-05-10|Amulet Pharmaceuticals, Inc.|Multi-phasic nitric oxide and drug co-eluting stent coatings|

---

WO2007053292A2|2005-10-31|2007-05-10|Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services|Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates|

---

EP1790335A1|2005-11-14|2007-05-30|NOLabs AB|Composition and its use for the manufacture of a medicament for treating, prophylactically treating, preventing cancer and/or infections in the urinary tract|

---

EP1954685A4|2005-11-16|2009-11-11|Nitromed Inc|Furoxan compounds, compositions and methods of use|

---

WO2007057763A2|2005-11-18|2007-05-24|Pulmonox Technologies Corporation|Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant|

---

CN101378792A|2005-12-02|2009-03-04|密执安大学评议会|Polymer compositions, coatings and devices, and methods of making and using the same|

---

US20070129690A1|2005-12-02|2007-06-07|Joel Rosenblatt|Catheter with polymeric coating|

---

US20070196327A1|2005-12-06|2007-08-23|Amulet Pharmaceuticals, Inc.|Nitric oxide releasing polymers|

---

WO2007076053A2|2005-12-21|2007-07-05|Nitrox, Llc|Stable s-nitrosothiol formulations|

---

WO2007084533A2|2006-01-17|2007-07-26|The University Of Akron|Debridement method using topical nitric oxide donor devices and compositions|

---

US20070225250A1|2006-01-26|2007-09-27|Bebaas, Inc.|Cobalamin compositions for the treatment of cancer|

---

EP1983975B1|2006-02-03|2015-07-29|Giulio Cossu|Method of treatment for muscular dystrophy|

---

KR20080097989A|2006-02-03|2008-11-06|니콕스 에스. 에이.|Use of nitrooxyderivative of drug for the treatment of muscular dystrophies|

---

US20070202155A1|2006-02-03|2007-08-30|Cure Therapeutics, Inc.|Low dose no donor-containing transdermal patch|

---

US20070203242A1|2006-02-27|2007-08-30|Calwood Nutritionals, Inc.|Method for treating gastric reflux|

---

US20070219208A1|2006-02-27|2007-09-20|Balaraman Kalyanaraman|Methods for Treating Cancer|

---

US7645748B2|2006-04-03|2010-01-12|Forbes Medi-Tech Inc.|Sterol/stanol phosphorylnitroderivatives and use thereof|

---

US7645749B2|2006-04-03|2010-01-12|Forbes Medi-Tech Inc.|Sterol/stanol nitroderivatives and use thereof|

---

US20090186859A1|2006-04-24|2009-07-23|The United States Of America, As Represented By The Sec., Dept. Of Health And Human Services|Diazeniumdiolated non-steroidal anti-inflammatory drugs, compositions thereof, and related methods|

---

US8241619B2|2006-05-15|2012-08-14|Medtronic Vascular, Inc.|Hindered amine nitric oxide donating polymers for coating medical devices|

---

US20080171351A1|2006-05-22|2008-07-17|University Of Notre Dame Du Lac|Probes for anionic cell surface detection|

---

WO2007149437A1|2006-06-16|2007-12-27|Alltech, Inc.|Reduction of antibiotic resistance in bacteria|

---

US8333997B2|2006-06-21|2012-12-18|Albert Einstein College Of Medicine Of Yeshiva University|Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof|

---

WO2008110872A2|2006-06-23|2008-09-18|Foamix Ltd.|Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses|

---

WO2008038147A2|2006-07-05|2008-04-03|Foamix Ltd.|Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof|

---

WO2008012845A1|2006-07-26|2008-01-31|Stmicroelectronics S.R.L.|Use of nitroaniline derivatives for the production of nitric oxide|

---

US20080025972A1|2006-07-26|2008-01-31|Duke University|Treating sex steriod responsive disorders|

---

CN103494620B|2006-08-03|2016-04-20|利兰斯坦福青年大学托管委员会|Be used for the treatment of or prevent the equipment of scar and/or cicatrix and binder and method thereof and external member|

---

GB0616350D0|2006-08-17|2006-09-27|Univ St Andrews|Adsorption and release of nitric oxide in metal organic frameworks|

---

EP1895012A1|2006-08-30|2008-03-05|Universitätsklinikum Freiburg|Method for inducing tumor apoptosis by increasing nitric oxide levels|

---

BRPI0716210A2|2006-08-30|2013-11-12|Southeastern Medical Technologies|METHODS, COMPOSITIONS AND APPARATUS FOR TREATING WOUNDS WITH DIFFERENT PRESSURES OF THE ATMOSPHERIC|

---

US20080166303A1|2006-09-08|2008-07-10|Dov Tamarkin|Colored or colorable foamable composition and foam|

---

GB0618711D0|2006-09-22|2006-11-01|Univ Exeter|Agricultural treatment|

---

US20080076721A1|2006-09-25|2008-03-27|Sal Abraham|Use of branched chain fatty acid amino acid salts and compositions thereof|

---

US20080206155A1|2006-11-14|2008-08-28|Foamix Ltd.|Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses|

---

US20080260655A1|2006-11-14|2008-10-23|Dov Tamarkin|Substantially non-aqueous foamable petrolatum basedpharmaceutical and cosmetic compositions and their uses|

---

US10322155B2|2006-11-15|2019-06-18|Arthritis Relief Plus Ltd.|Topical formulation and uses thereof|

---

GB0623531D0|2006-11-25|2007-01-03|Univ St Andrews|Nitric oxide storage and production|

---

EP2097065A2|2006-11-29|2009-09-09|Foamix Ltd.|Foamable waterless compositions with modulating agents|

---

US20080175881A1|2007-01-18|2008-07-24|Boston Scientific Scimed, Inc.|Blood-contacting medical devices for the release of nitric oxide and anti-restenotic agents|

---

EP2114427B1|2007-01-30|2014-06-25|New York University|Peptides for treatment of conditions associated with nitric oxide|

---

ES2604562T3|2007-02-05|2017-03-07|Nicox Science Ireland|Nitric Oxide Donor Compounds|

---

US20080193385A1|2007-02-08|2008-08-14|Todd Maibach|Compositions and methods for treating neuropathy|

---

US20080193566A1|2007-02-09|2008-08-14|Miller Christopher C|Use of high dose concentrations of gaseous nitric oxide|

---

WO2008100591A2|2007-02-14|2008-08-21|The General Hospital Corporation|Modulation of nitric oxide signaling to normalize tumor vasculature|

---

US7811600B2|2007-03-08|2010-10-12|Medtronic Vascular, Inc.|Nitric oxide donating medical devices and methods of making same|

---

US7851465B2|2007-03-09|2010-12-14|The Regents Of The University Of Michigan|Compositions and methods relating to novel compounds and targets thereof|

---

CA2687640A1|2007-03-27|2008-10-02|Nolabs Ab|Topical dermal delivery device for nitric oxide delivery|

---

US8598368B2|2007-04-20|2013-12-03|Duke University|Stable neutral nitric oxide source|

---

US20100255062A1|2007-06-01|2010-10-07|Amulet Pharmaceuticals, Inc.|Compounds, polymers and methods for treating gastrointestinal dysfunction|

---

US20100247680A1|2007-06-15|2010-09-30|Csaba Szabo|Compositions and Methods to Modulate Angiogenesis|

---

US8273828B2|2007-07-24|2012-09-25|Medtronic Vascular, Inc.|Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation|

---

DK2170157T3|2007-07-26|2016-12-12|Univ Duke|Measuring the quantity of bound and combined nitric oxide in blood|

---

US8636982B2|2007-08-07|2014-01-28|Foamix Ltd.|Wax foamable vehicle and pharmaceutical compositions thereof|

---

GB0715554D0|2007-08-09|2007-09-19|Insense Ltd|Improvements relating to skin dressings|

---

GB0715556D0|2007-08-09|2007-09-19|Insense Ltd|Improvements relating to skin dressings|

---

CA2599082A1|2007-08-27|2009-02-27|Ping I. Lee|Supramacromolecular polymer complexes providing controlled nitric oxide release for healing wounds|

---

WO2009071990A2|2007-08-31|2009-06-11|Topigen Pharmaceuticals Inc.|No-donating cordicosteroid with improved pharmacokinetic, anti-inflammatory and vasodilatory properties|

---

US8617100B2|2007-09-04|2013-12-31|Foamix Ltd.|Device for delivery of a foamable composition|

---

CN101835502A|2007-09-21|2010-09-15|伊诺克斯生物制药公司|Antimicrobial gas-releasing ear drainage tubes|

---

US8399005B2|2007-10-12|2013-03-19|University Of North Carolina At Chapel Hill|Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents|

---

US20090110933A1|2007-10-30|2009-04-30|Searete Llc, A Limited Liability Corporation Of The State Of Delaware|Systems and devices related to nitric oxide releasing materials|

---

US20090112193A1|2007-10-30|2009-04-30|Searete Llc, A Limited Liability Corporation Of The State Of Delaware|Systems and devices that utilize photolyzable nitric oxide donors|

---

US7862598B2|2007-10-30|2011-01-04|The Invention Science Fund I, Llc|Devices and systems that deliver nitric oxide|

---

US8349262B2|2007-10-30|2013-01-08|The Invention Science Fund I, Llc|Nitric oxide permeable housings|

---

US20090112055A1|2007-10-30|2009-04-30|Searete Llc, A Limited Liability Corporation Of The State Of Delaware|Sleeves configured to facilitate release of nitric oxide|

---

US20090112197A1|2007-10-30|2009-04-30|Searete Llc|Devices configured to facilitate release of nitric oxide|

---

US8877508B2|2007-10-30|2014-11-04|The Invention Science Fund I, Llc|Devices and systems that deliver nitric oxide|

---

US7897399B2|2007-10-30|2011-03-01|The Invention Science Fund I, Llc|Nitric oxide sensors and systems|

---

US8221690B2|2007-10-30|2012-07-17|The Invention Science Fund I, Llc|Systems and devices that utilize photolyzable nitric oxide donors|

---

US8642093B2|2007-10-30|2014-02-04|The Invention Science Fund I, Llc|Methods and systems for use of photolyzable nitric oxide donors|

---

WO2009064861A2|2007-11-13|2009-05-22|The United States Of America, As Represented By The Secretary, Department Of Health And Human Services|Nitric oxide-releasing diazeniumdiolated polymers, compositions, medical devices, and uses thereof|

---

US20090130029A1|2007-11-21|2009-05-21|Foamix Ltd.|Glycerol ethers vehicle and pharmaceutical compositions thereof|

---

US9439857B2|2007-11-30|2016-09-13|Foamix Pharmaceuticals Ltd.|Foam containing benzoyl peroxide|

---

WO2009073643A2|2007-12-03|2009-06-11|Cleveland State University|Nitric oxide release coatings incorporating nitric oxide synthase enzyme|

---

WO2009090495A2|2007-12-07|2009-07-23|Foamix Ltd.|Oil and liquid silicone foamable carriers and formulations|

---

WO2009073940A2|2007-12-12|2009-06-18|Universidade Estadual De Campinas - Unicamp|Use of phthalimide derivatives in the treatment of diseases|

---

IE20070934A1|2007-12-21|2009-06-24|Trinity College Dublin|Efficient aspirin prodrugs|

---

WO2009086470A2|2007-12-27|2009-07-09|Aires Pharmaceuticals, Inc.|Aerosolized nitrite and nitric oxide - donating compounds and uses thereof|

---

CA2709660C|2008-01-04|2018-06-05|Nestec S.A.|Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions|

---

RU2528097C2|2008-01-31|2014-09-10|Вандербилт Юнивёсити|Methods and formulations for treating subarachnoidal haemorrhage of coronary and arterial aneurism|

---

US8720436B2|2008-01-31|2014-05-13|Genosys, Inc.|Nitric oxide gel apparatus and method|

---

CA2706082C|2008-02-07|2017-10-03|Nicox S.A.|Nitric oxide donor compounds|

---

US20090222088A1|2008-02-29|2009-09-03|Medtronic Vascular, Inc.|Secondary Amine Containing Nitric Oxide Releasing Polymer Composition|

---

US20090232863A1|2008-03-17|2009-09-17|Medtronic Vascular, Inc.|Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers|

---

US20090232868A1|2008-03-17|2009-09-17|Medtronic Vascular, Inc.|Nitric Oxide Releasing Polymer Composition|

---

WO2009124379A1|2008-04-09|2009-10-15|Enox Biopharma, Inc.|Biofilm-inhibiting catheters and tubings|

---

WO2009131931A1|2008-04-21|2009-10-29|3M Innovative Properties Company|Nitric oxide-releasing compositions, devices and methods|

---

US20120141384A1|2008-05-06|2012-06-07|Dov Tamarkin|Antibacterial conjugated boronic acids and pharmaceutical compositions thereof|

---

WO2009155690A1|2008-06-24|2009-12-30|Micropharma Limited|Nitric oxide compositions and devices and methods for cosmesis|

---

US8852640B2|2008-07-03|2014-10-07|Ecole Polytechnique Federale De Lausanne |Micelles for delivery of nitric oxide|

---

KR101199580B1|2008-08-06|2013-11-27|에델프라우|Nanoemulsion for topical administration|

---

US20100040703A1|2008-08-13|2010-02-18|Chris Miller|Use of nitric oxide|

---

US8580912B2|2008-09-19|2013-11-12|Northwestern University|Biodegradable nitric oxide generating polymers and related biomedical devices|

---

US7807716B2|2008-09-24|2010-10-05|Oral Delivery Technology Ltd.|Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use|

---

US20100086530A1|2008-10-06|2010-04-08|Martinov Norman P|Cancer-tumor necrosis by artery nutrient-oxygen blocking|

---

US9700246B2|2008-10-15|2017-07-11|The University Of Tennessee Research Foundation|Method and device for detection of bioavailable drug concentration in a fluid sample|

---

US20100099766A1|2008-10-16|2010-04-22|Novartis Ag|Topical NSAID compositions having sensate component|

---

US20100098733A1|2008-10-16|2010-04-22|Novan, Inc.|Nitric oxide releasing particles for oral care applications|

---

WO2010048724A1|2008-10-30|2010-05-06|Chris Miller|Nitric oxide-releasing dressings|

---

US20100166603A1|2008-10-31|2010-07-01|Noxilizer, Inc.|Powder Sterilization|

---

US8158187B2|2008-12-19|2012-04-17|Medtronic Vascular, Inc.|Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices|

---

US20100197702A1|2009-02-04|2010-08-05|Hellberg Mark R|Ophthalmic composition with nitric oxide donor compound and method of forming and using same|

---

EP2398761A4|2009-02-18|2015-11-04|Bezwada Biomedical Llc|Controlled release of nitric oxide and drugs from functionalized macromers and oligomers|

---

US8062653B2|2009-02-18|2011-11-22|Bezwada Biomedical, Llc|Controlled release of nitric oxide and drugs from functionalized macromers and oligomers|

---

US9278113B2|2009-03-30|2016-03-08|The Board Of Regents, The University Of Texas System|Titanium dioxide nanotubes for production and delivery of nitric oxide and methods for production thereof|

---

US8236341B2|2009-04-02|2012-08-07|Medtronic Vascular, Inc.|Poly polymer with nitric oxide donating surface|

---

US8709465B2|2009-04-13|2014-04-29|Medtronic Vascular, Inc.|Diazeniumdiolated phosphorylcholine polymers for nitric oxide release|

---

US20100286272A1|2009-05-08|2010-11-11|Perricone Nicholas V|Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications|

---

US8613958B2|2009-06-22|2013-12-24|Geno Llc|Nitric oxide therapies|

---

JP2012532960A|2009-07-07|2012-12-20|コンバテックテクノロジーズインコーポレイテッド|Amphiphilic silicone copolymers for the application of pressure sensitive adhesives|

---

EP2467127A1|2009-08-21|2012-06-27|Novan, Inc.|Topical gels|

---

EP2467173B8|2009-08-21|2019-06-19|Novan, Inc.|Wound dressings, methods of using the same and methods of forming the same|

---

US20110059189A1|2009-09-08|2011-03-10|Cisne Enterprises Inc.|Method and composition for treating cancer, effecting apoptosis and treating retroviral infections|

---

US20110086234A1|2009-10-13|2011-04-14|Nathan Stasko|Nitric oxide-releasing coatings|

---

RU2012126084A|2009-11-23|2013-12-27|Сипла Лимитед|FOAM COMPOSITION FOR LOCAL USE|

---

US8591876B2|2010-12-15|2013-11-26|Novan, Inc.|Methods of decreasing sebum production in the skin|

---

EP2665763B1|2011-01-20|2015-08-26|Novan, Inc.|Temperature controlled sol-gel co-condensation|

---

EP2681286B1|2011-02-28|2018-08-15|Novan, Inc.|Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same|

---

WO2012153331A2|2011-05-09|2012-11-15|Topical Therapeutic Agent Ltd.|Nitric oxide-sequestering topical formulations|

---

WO2013006613A1|2011-07-05|2013-01-10|Novan, Inc.|Methods of manufacturing topical compositions and apparatus for same|

---

JP6277124B2|2011-07-05|2018-02-07|ノヴァン，インコーポレイテッド|Topical composition|

---

ES2658897T3|2011-08-24|2018-03-12|Novan, Inc.|Adjustable nitric oxide releasing macromolecules that have multiple nitric oxide donor structures|

---

US9669041B2|2011-10-27|2017-06-06|Novan, Inc.|Nitric oxide releasing bath compositions and methods of using the same|

---

WO2013138073A1|2012-03-13|2013-09-19|Novan, Inc.|Methods of modulating steroid hormone activity|

---

CA2865526C|2012-03-14|2020-06-23|Novan, Inc.|Nitric oxide releasing pharmaceutical compositions|

---

WO2014028847A1|2012-08-17|2014-02-20|The University Of North Carolina At Chapel Hill|Water soluble nitric oxide-releasing polyglucosamines and uses thereof|

---

US9187501B2|2012-08-28|2015-11-17|The University Of North Carolina At Chapel Hill|Nitric oxide-releasing nanorods and their methods of use|

---

US9855211B2|2013-02-28|2018-01-02|Novan, Inc.|Topical compositions and methods of using the same|US9427605B2|2005-03-24|2016-08-30|Novan, Inc.|Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor|

---

EP2467127A1|2009-08-21|2012-06-27|Novan, Inc.|Topical gels|

---

US8591876B2|2010-12-15|2013-11-26|Novan, Inc.|Methods of decreasing sebum production in the skin|

---

EP2665763B1|2011-01-20|2015-08-26|Novan, Inc.|Temperature controlled sol-gel co-condensation|

---

US20140086857A1|2011-05-13|2014-03-27|Quadsil, Inc.|Compositions Comprising Siloxane Polymer|

---

JP6277124B2|2011-07-05|2018-02-07|ノヴァン，インコーポレイテッド|Topical composition|

---

WO2013006613A1|2011-07-05|2013-01-10|Novan, Inc.|Methods of manufacturing topical compositions and apparatus for same|

---

ES2658897T3|2011-08-24|2018-03-12|Novan, Inc.|Adjustable nitric oxide releasing macromolecules that have multiple nitric oxide donor structures|

---

ES2756848T3|2011-10-08|2020-04-27|Next Science IP Holdings Pty Ltd|Antimicrobial compositions and methods that employ them|

---

US9592241B2|2011-12-27|2017-03-14|Cmpd Licensing, Llc|Silicone-based composition for skin treatment|

---

CA2865526C|2012-03-14|2020-06-23|Novan, Inc.|Nitric oxide releasing pharmaceutical compositions|

---

US9855211B2|2013-02-28|2018-01-02|Novan, Inc.|Topical compositions and methods of using the same|

---

CA2911464C|2013-05-02|2021-06-08|Next Science, Llc|High osmolarity antimicrobial composition containing one or more organic solvents|

---

BR112016002387B1|2013-08-08|2019-05-21|Novan, Inc.|Topical Pharmaceutical Compositions, and Method for Storage|

---

WO2016022170A1|2014-08-08|2016-02-11|Novan, Inc.|Topical emulsions|

---

US9226890B1|2013-12-10|2016-01-05|Englewood Lab, Llc|Polysilicone base for scar treatment|

---

BR112016015082B1|2014-01-27|2021-01-05|Unilever Nv|hair treatment composition|

---

AU2015273123A1|2014-06-09|2016-12-22|Klox Technologies Inc.|Silicone-based biophotonic compositions and uses thereof|

---

US10322082B2|2014-07-11|2019-06-18|Novan, Inc.|Topical antiviral compositions and methods of using the same|

---

EP3166593B1|2014-07-11|2020-05-20|Novan, Inc.|Topical antiviral compositions and methods of using the same|

---

US10925689B2|2014-07-14|2021-02-23|Novan, Inc.|Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same|

---

CN107920532A|2015-07-17|2018-04-17|贴近科学Ip控股私人有限公司|Antimicrobial compositions with anti-endospore effect|

---

WO2017019614A1|2015-07-28|2017-02-02|Novan, Inc.|Combinations and methods for the treatment and/or prevention of fungal infections|

---

AU2016323770A1|2015-09-16|2018-03-29|Dfb Soria, Llc|Delivery of drug nanoparticles and methods of use thereof|

---

TWI607067B|2015-09-25|2017-12-01|立得光電科技股份有限公司|Anti-bacterial and anti-mould surface coating, and manufacturing method thereof|

---

WO2017151905A1|2016-03-02|2017-09-08|Novan, Inc.|Compositions for treating inflammation and methods of treating the same|

---

EP3442502A4|2016-04-13|2019-11-06|Novan, Inc.|Compositions, systems, kits, and methods for treating an infection|

---

CN105832656B|2016-05-25|2018-10-09|暨南大学|It is a kind of to carry nitric oxide production carboxyl chitosan-polyethyleneimine hydrogel and its preparation method and application|

---

WO2018170207A1|2017-03-15|2018-09-20|Dfb Soria, Llc|Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes|

---

KR20200014270A|2017-03-15|2020-02-10|디에프비 소리아, 엘엘씨|Topical therapies for the treatment of skin malignancies with taxane nanoparticles|

---

EP3612200A4|2017-04-21|2020-12-30|Phi Therapeutics, Inc.|Compositions comprising propionibacterium acnes bacteriophages for treating acne|

---

CN111601617A|2017-12-13|2020-08-28|上海岸阔医药科技有限公司|Method for preventing or treating diseases related to EGFR inhibition|

---

EP3782618A4|2018-04-16|2022-01-26|Onquality Pharmaceuticals China Ltd|Method for preventing or treating side effects of cancer therapy|

---

RU2713943C1|2019-10-28|2020-02-11|Александр Ливиевич Ураков|Gel for children's skin|

法律状态:
2018-03-06| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-03-27| B15K| Others concerning applications: alteration of classification|Ipc: A61K 31/80 (2006.01), A61K 9/00 (2006.01), A61K 9/ |

---

2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-07-02| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-12-24| B15K| Others concerning applications: alteration of classification|Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 31/80 , A61K 9/00 , A61K 9/06 , A61K 31/655 , A61K 33/00 , A61K 47/24 , A61K 47/59 , A61K 47/69 , A61P 17/02 , A61P 17/10 Ipc: A61L 15/22 (1990.01), A61L 15/44 (1990.01), A61L 1 |

---

2019-12-24| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-03-31| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-05-19| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/08/2010, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US23593309P| true| 2009-08-21|2009-08-21|

---

PCT/US2010/046173|WO2011022652A1|2009-08-21|2010-08-20|Topical gels|

---